Omega Healthcare Investors (OHI) 10-Q 7 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 27, 2017
Document And Entity Information [Line Items]
Entity Registrant Name	OMEGA HEALTHCARE INVESTORS INC
Entity Central Index Key	888,491
Trading Symbol	ohi
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock Shares Outstanding		198,073,305
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
OHI Healthcare Properties Limited Partnership
Document And Entity Information [Line Items]
Entity Registrant Name	OHI Healthcare Properties Limited Partnership
Entity Central Index Key	1,639,315
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock Shares Outstanding		0
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Sep. 30, 2017	Dec. 31, 2016
Real estate properties
Real estate investments (see Note 2)		$ 7,977,043	$ 7,566,358
Less accumulated depreciation		(1,432,154)	(1,240,336)
Real estate investments - net		6,544,889	6,326,022
Investments in direct financing leases - net		364,997	601,938
Mortgage notes receivable - net		666,606	639,343
Total		7,576,492	7,567,303
Other investments - net		273,821	256,846
Investment in unconsolidated joint venture		37,733	48,776
Assets held for sale - net		17,324	52,868
Total investments		7,905,370	7,925,793
Cash and cash equivalents		24,318	93,687
Restricted cash		10,596	13,589
Accounts receivable - net		269,746	240,035
Goodwill		644,571	643,474
Other assets		36,045	32,682
Total assets		8,890,646	8,949,260
LIABILITIES AND EQUITY
Revolving line of credit		365,000	190,000
Term loans - net		903,221	1,094,343
Secured borrowings - net	[1]	53,419	54,365
Unsecured borrowings - net		3,322,888	3,028,146
Accrued expenses and other liabilities		285,690	360,514
Deferred income taxes		17,589	9,906
Total liabilities		4,947,807	4,737,274
Equity:
Common stock $.10 par value authorized - 350,000 shares, issued and outstanding - 198,065 shares as of September 30, 2017 and 196,142 as of December 31, 2016		19,806	19,614
Common stock - additional paid-in capital		4,925,908	4,861,408
Cumulative net earnings		1,776,956	1,738,937
Cumulative dividends paid		(3,080,999)	(2,707,387)
Accumulated other comprehensive loss		(34,843)	(53,827)
Total stockholders' equity		3,606,828	3,858,745
Noncontrolling interest		336,011	353,241
Total equity		3,942,839	4,211,986
Owners' Equity:
Total liabilities and equity		8,890,646	8,949,260
OHI Healthcare Properties Limited Partnership
Real estate properties
Real estate investments (see Note 2)		7,977,043	7,566,358
Less accumulated depreciation		(1,432,154)	(1,240,336)
Real estate investments - net		6,544,889	6,326,022
Investments in direct financing leases - net		364,997	601,938
Mortgage notes receivable - net		666,606	639,343
Total		7,576,492	7,567,303
Other investments - net		273,821	256,846
Investment in unconsolidated joint venture		37,733	48,776
Assets held for sale - net		17,324	52,868
Total investments		7,905,370	7,925,793
Cash and cash equivalents		24,318	93,687
Restricted cash		10,596	13,589
Accounts receivable - net		269,746	240,035
Goodwill		644,571	643,474
Other assets		36,045	32,682
Total assets		8,890,646	8,949,260
LIABILITIES AND EQUITY
Term loans - net		99,390	100,000
Secured borrowings - net		53,419	54,365
Accrued expenses and other liabilities		230,127	302,959
Deferred income taxes		17,589	9,906
Intercompany loans payable		4,547,282	4,270,044
Total liabilities		4,947,807	4,737,274
Owners' Equity:
General partners' equity		3,606,828	3,858,745
Limited partners' equity		336,011	353,241
Total owners' equity		3,942,839	4,211,986
Total liabilities and equity		$ 8,890,646	$ 8,949,260
[1]	These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares shares in Thousands	Sep. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized	350,000	350,000
Common stock, shares issued	198,065	196,142
Common stock, shares outstanding	198,065	196,142

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue
Rental income	$ 194,063	$ 185,837	$ 580,597	$ 548,994
Income from direct financing leases	614	15,611	31,722	46,574
Mortgage interest income	16,920	15,996	49,173	53,973
Other investment income - net	7,245	6,229	21,437	14,642
Miscellaneous income	796	965	4,250	2,158
Total operating revenues	219,638	224,638	687,179	666,341
Expenses
Depreciation and amortization	71,925	68,316	212,268	196,254
General and administrative	11,560	12,428	35,625	34,715
Acquisition costs		2,309	(22)	9,584
Impairment loss on real estate properties	17,837	17,275	35,610	58,726
Impairment loss on direct financing leases	194,659		197,968
Provision for uncollectible accounts	11,899	(3)	13,667	3,967
Total operating expenses	307,880	100,325	495,116	303,246
(Loss) income before other income and expense	(88,242)	124,313	192,063	363,095
Other income (expense)
Interest income	4	157	262	169
Interest expense	(47,383)	(42,855)	(140,509)	(119,728)
Interest - amortization of deferred financing costs	(2,228)	(2,502)	(7,273)	(6,844)
Interest - refinancing costs		(1,815)	(21,965)	(2,113)
Contractual settlement			10,412
Realized gain (loss) on foreign exchange	95	(222)	235	(244)
Total other expense	(49,512)	(47,237)	(158,838)	(128,760)
(Loss) income before gain on assets sold	(137,754)	77,076	33,225	234,335
Gain on assets sold - net	693	5,139	7,491	19,931
(Loss) income from continuing operations	(137,061)	82,215	40,716	254,266
Income taxes	(999)	(81)	(2,690)	(782)
Income from unconsolidated joint venture	545		1,728
Net (loss) income	(137,515)	82,134	39,754	253,484
Net loss (income) attributable to noncontrolling interest	5,837	(3,585)	(1,735)	(11,328)
Net (loss) income available to common stockholders	$ (131,678)	$ 78,549	$ 38,019	$ 242,156
Basic:
Net (loss) income available to common stockholders (in dollars per share)	$ (0.67)	$ 0.40	$ 0.19	$ 1.27
Diluted:
Net (loss) income (in dollars per share)	(0.67)	0.40	0.19	1.26
Diluted:
Dividends declared per common share (in dollars per share)	$ 0.64	$ 0.60	$ 1.89	$ 1.75
Weighted-average shares outstanding, basic (in shares)	197,890	194,123	197,445	190,444
Weighted-average shares outstanding, diluted (in shares)	206,662	204,078	206,502	200,528
OHI Healthcare Properties Limited Partnership
Revenue
Rental income	$ 194,063	$ 185,837	$ 580,597	$ 548,994
Income from direct financing leases	614	15,611	31,722	46,574
Mortgage interest income	16,920	15,996	49,173	53,973
Other investment income - net	7,245	6,229	21,437	14,642
Miscellaneous income	796	965	4,250	2,158
Total operating revenues	219,638	224,638	687,179	666,341
Expenses
Depreciation and amortization	71,925	68,316	212,268	196,254
General and administrative	11,560	12,428	35,625	34,715
Acquisition costs		2,309	(22)	9,584
Impairment loss on real estate properties	17,837	17,275	35,610	58,726
Impairment loss on direct financing leases	194,659		197,968
Provision for uncollectible accounts	11,899	(3)	13,667	3,967
Total operating expenses	307,880	100,325	495,116	303,246
(Loss) income before other income and expense	(88,242)	124,313	192,063	363,095
Other income (expense)
Interest income	4	157	262	169
Interest expense	(47,383)	(42,855)	(140,509)	(119,728)
Interest - amortization of deferred financing costs	(2,228)	(2,502)	(7,273)	(6,844)
Interest - refinancing costs		(1,815)	(21,965)	(2,113)
Contractual settlement			10,412
Realized gain (loss) on foreign exchange	95	(222)	235	(244)
Total other expense	(49,512)	(47,237)	(158,838)	(128,760)
(Loss) income before gain on assets sold	(137,754)	77,076	33,225	234,335
Gain on assets sold - net	693	5,139	7,491	19,931
(Loss) income from continuing operations	(137,061)	82,215	40,716	254,266
Income taxes	(999)	(81)	(2,690)	(782)
Income from unconsolidated joint venture	545		1,728
Net (loss) income	$ (137,515)	$ 82,134	$ 39,754	$ 253,484
Basic:
Net (loss) income (in dollars per share)	$ (0.67)	$ 0.40	$ 0.19	$ 1.27
Diluted:
Net (loss) income (in dollars per share)	(0.67)	0.40	0.19	1.26
Dividends declared per common share (in dollars per share)	$ 0.64	$ 0.60	$ 1.89	$ 1.75
Weighted-average Omega OP Units outstanding, basic (in shares)	206,662	202,985	206,231	199,354
Weighted-average Omega OP Units outstanding, diluted (in shares)	206,662	204,078	206,502	200,528

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net (loss) income	$ (137,515)	$ 82,134	$ 39,754	$ 253,484
Other comprehensive income (loss):
Foreign currency translation	5,022	(6,845)	19,630	(33,411)
Derivative instruments	2,351	980	198	(12,094)
Total other comprehensive income (loss)	7,373	(5,865)	19,828	(45,505)
Comprehensive (loss) income	(130,142)	76,269	59,582	207,979
Comprehensive loss (income) attributable to noncontrolling interest	5,524	(3,329)	(2,579)	(9,282)
Comprehensive (loss) income attributable to common stockholders	(124,618)	72,940	57,003	198,697
OHI Healthcare Properties Limited Partnership
Net (loss) income	(137,515)	82,134	39,754	253,484
Other comprehensive income (loss):
Foreign currency translation	5,022	(6,845)	19,630	(33,411)
Derivative instruments	2,351	980	198	(12,094)
Total other comprehensive income (loss)	7,373	(5,865)	19,828	(45,505)
Comprehensive (loss) income	$ (130,142)	$ 76,269	$ 59,582	$ 207,979

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($) $ in Thousands	Common Stock Par Value	Additional Paid-in Capital	Cumulative Net Earnings	Cumulative Dividends	Accumulated Other Comprehensive Loss	Total Stockholders' Equity	Noncontrolling Interest	Total
Balance (196,142 common shares & 8,862 Omega OP Units) at Dec. 31, 2016	$ 19,614	$ 4,861,408	$ 1,738,937	$ (2,707,387)	$ (53,827)	$ 3,858,745	$ 353,241	$ 4,211,986
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Grant of restricted stock to company directors (32 shares at $31.23 per share)	3	(3)
Stock-based compensation expense		11,350				11,350		11,350
Vesting/exercising of equity compensation plan, net of tax withholdings (114 shares)	11	(2,131)				(2,120)		(2,120)
Dividend reinvestment and stock purchase plan (957 shares at an average of $31.49 per share)	96	30,040				30,136		30,136
Grant of stock as payment of directors fees (5 shares at an average of $32.18 per share)	1	149				150		150
Deferred compensation directors (8 shares at $32.10 per share)		38				38		38
Equity Shelf Program (718 shares at $30.92 per share, net of issuance costs)	72	22,124				22,196		22,196
Common dividends declared ($1.89 per share)				(373,612)		(373,612)		(373,612)
Conversion of Omega OP Units to common stock (89 shares at $32.91 per share)	9	2,933				2,942		2,942
Redemption of Omega OP Units (90 units)							(2,990)	(2,990)
Omega OP Units distributions							(16,819)	(16,819)
Comprehensive income:
Foreign currency translation					18,795	18,795	835	19,630
Derivative instruments					189	189	9	198
Net income			38,019			38,019	1,735	39,754
Total comprehensive income								59,582
Balance (198,065 shares & 8,772 Omega OP Units) at Sep. 30, 2017	$ 19,806	$ 4,925,908	$ 1,776,956	$ (3,080,999)	$ (34,843)	$ 3,606,828	$ 336,011	$ 3,942,839

CONSOLIDATED STATEMENT OF CHAN7

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited) (Parentheticals) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Increase (Decrease) In Stockholders' Equity [Roll Forward]
Balance (in shares)	196,142
Grant of restricted stock (in shares)	32
Grant of restricted stock (in dollars per share)	$ 31.23
Vesting/exercising of equity compensation plan (in shares)	114
Dividend reinvestment and stock purchase plan (in shares)	957
Dividend reinvestment and stock purchase plan (in dollars per share)	$ 31.49
Grant of stock as payment of directors fees (in shares)	5
Grant of stock as payment of fees (in dollars per share)	$ 32.18
Deferred compensation directors (in shares)	8
Deferred compensation directors (in dollars per share)	$ 32.10
Equity shelf program (in shares)	718
Equity shelf program (in dollars per share)	$ 30.92
Common dividends (in dollars per share)	$ 1.89
Conversion of OP Units to Common stock (in shares)	89
Conversion of OP Units to Common stock (in dollars per share)	$ 32.91
Redemption of OP Units (in units)	90
Balance (in shares)	198,065	196,142
Balance (in units)	8,772	8,862

CONSOLIDATED STATEMENT OF CHAN8

CONSOLIDATED STATEMENT OF CHANGES IN OWNERS' EQUITY (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($) shares in Thousands, $ in Thousands	OHI Healthcare Properties Limited PartnershipGeneral Partners' Omega OP Units	OHI Healthcare Properties Limited PartnershipLimited Partners' Omega OP Units	OHI Healthcare Properties Limited Partnership	Total
Balance at Dec. 31, 2016	$ 3,858,745	$ 353,241	$ 4,211,986
Balance (in units) at Dec. 31, 2016	196,142	8,862	205,004
Increase (Decrease) in Partners' Capital [Roll Forward]
Contributions from partners	$ 64,692		$ 64,692
Contributions from partners (in units)	1,923		1,923
Distributions to partners	$ (373,612)	$ (16,819)	$ (390,431)
Omega OP Unit redemptions		$ (2,990)	$ (2,990)
Omega OP Unit redemptions (in units)		(90)	(90)
Comprehensive income:
Foreign currency translation	18,795	$ 835	$ 19,630	$ 19,630
Derivative instruments	189	9	198	198
Net income	38,019	1,735	39,754	39,754
Total comprehensive income			59,582	$ 59,582
Balance at Sep. 30, 2017	$ 3,606,828	$ 336,011	$ 3,942,839
Balance (in units) at Sep. 30, 2017	198,065	8,772	206,837

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities
Net income	$ 39,754	$ 253,484
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	212,268	196,254
Impairment loss on real estate properties	35,610	58,726
Impairment loss on direct financing leases	197,968
Provision for uncollectible accounts	13,667	3,967
Refinancing costs and amortization of deferred financing costs	17,468	8,957
Accretion of direct financing leases	(6,139)	(8,999)
Stock-based compensation expense	11,350	10,116
Gain on assets sold - net	(7,491)	(19,931)
Amortization of acquired in-place leases - net	(9,101)	(10,957)
Effective yield receivable on mortgage notes	(1,558)	(209)
Change in operating assets and liabilities - net:
Contractual receivables	(35,418)	203
Straight-line rent receivables	(13,559)	(29,959)
Lease inducements	1,342	1,942
Other operating assets and liabilities	(25,900)	(6,357)
Net cash provided by operating activities	430,261	457,237
Cash flows from investing activities
Acquisition of real estate	(345,268)	(959,748)
Cash acquired	2,341
Investments in construction in progress	(69,409)	(44,113)
Investments in direct financing leases	(6,951)	(1,079)
Proceeds from sale of direct financing lease assets	33,074
Placement of mortgage loans	(29,324)	(27,895)
Distributions from unconsolidated joint venture	10,966
Proceeds from sale of real estate investments	69,788	64,746
Capital improvements to real estate investments	(25,293)	(31,408)
Proceeds from other investments	45,045	49,482
Investments in other investments	(86,075)	(242,999)
Collection of mortgage principal	1,058	58,149
Net cash used in investing activities	(400,048)	(1,134,865)
Cash flows from financing activities
Proceeds from credit facility borrowings	1,487,000	1,134,000
Payments on credit facility borrowings	(1,312,000)	(1,141,000)
Receipts of other long-term borrowings	1,346,749	1,048,173
Payments of other long-term borrowings	(1,252,463)	(180,934)
Payments of financing related costs	(29,198)	(11,770)
Receipts from dividend reinvestment plan	30,136	229,769
Payments for exercised options and restricted stock	(2,120)	(23,403)
Net proceeds from issuance of common stock	22,196
Dividends paid	(373,424)	(333,663)
Redemption of Omega OP Units	(48)	(732)
Distributions to Omega OP Unit Holders	(16,819)	(15,738)
Net cash (used in) provided by financing activities	(99,991)	704,702
Effect of foreign currency translation on cash and cash equivalents	409	69
(Decrease) increase in cash and cash equivalents	(69,369)	27,143
Cash and cash equivalents at beginning of period	93,687	5,424
Cash and cash equivalents at end of period	24,318	32,567
OHI Healthcare Properties Limited Partnership
Cash flows from operating activities
Net income	39,754	253,484
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	212,268	196,254
Impairment loss on real estate properties	35,610	58,726
Impairment loss on direct financing leases	197,968
Provision for uncollectible accounts	13,667	3,967
Refinancing costs and amortization of deferred financing costs	17,468	8,957
Accretion of direct financing leases	(6,139)	(8,999)
Stock-based compensation expense	11,350	10,116
Gain on assets sold - net	(7,491)	(19,931)
Amortization of acquired in-place leases - net	(9,101)	(10,957)
Effective yield receivable on mortgage notes	(1,558)	(209)
Change in operating assets and liabilities - net:
Contractual receivables	(35,418)	203
Straight-line rent receivables	(13,559)	(29,959)
Lease inducements	1,342	1,942
Other operating assets and liabilities	(25,900)	(6,357)
Net cash provided by operating activities	430,261	457,237
Cash flows from investing activities
Acquisition of real estate	(345,268)	(959,748)
Cash acquired	2,341
Investments in construction in progress	(69,409)	(44,113)
Investments in direct financing leases	(6,951)	(1,079)
Proceeds from sale of direct financing lease assets	33,074
Placement of mortgage loans	(29,324)	(27,895)
Distributions from unconsolidated joint venture	10,966
Proceeds from sale of real estate investments	69,788	64,746
Capital improvements to real estate investments	(25,293)	(31,408)
Proceeds from other investments	45,045	49,482
Investments in other investments	(86,075)	(242,999)
Collection of mortgage principal	1,058	58,149
Net cash used in investing activities	(400,048)	(1,134,865)
Cash flows from financing activities
Proceeds from intercompany loans payable from Omega	2,833,749	2,182,173
Repayment of intercompany loans payable to Omega	(2,564,463)	(1,321,934)
Payment of financing related costs incurred by Omega	(29,198)	(11,770)
Equity contributions from general partners	50,212	206,366
Distributions to general partners	(373,424)	(333,663)
Distributions to limited partners	(16,819)	(15,738)
Redemption of Omega OP Units	(48)	(732)
Net cash (used in) provided by financing activities	(99,991)	704,702
Effect of foreign currency translation on cash and cash equivalents	409	69
(Decrease) increase in cash and cash equivalents	(69,369)	27,143
Cash and cash equivalents at beginning of period	93,687	5,424
Cash and cash equivalents at end of period	$ 24,318	$ 32,567

BASIS OF PRESENTATION AND SIGNI

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Business Overview and Organization Omega Healthcare Investors, Inc. (“Omega”) was formed as a real estate investment trust (“REIT”) and incorporated in the State of Maryland on March 31, 1992. All of Omega's assets are owned directly or indirectly, and all of Omega's operations are conducted directly or indirectly, through its subsidiary, OHI Healthcare Properties Limited Partnership (“Omega OP”). Omega OP was formed as a limited partnership and organized in the State of Delaware on October 24, 2014. No substantive assets or activity occurred in Omega OP until the merger with Aviv REIT, Inc. on April 1, 2015. Unless stated otherwise or the context otherwise requires, the terms the “Company,” “we,” “our” and “us” means Omega and Omega OP, collectively. The Company has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States (“U.S.”) and the United Kingdom (“U.K.”). Our core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (“SNFs”) and, to a lesser extent, assisted living facilities (“ALFs”), independent living facilities and rehabilitation and acute care facilities. Our core portfolio consists of long-term leases and mortgage agreements. All of our leases are “triple-net” leases, which require the tenants to pay all property-related expenses. Our mortgage revenue derives from fixed rate mortgage loans, which are secured by first mortgage liens on the underlying real estate and personal property of the mortgagor. In April 2015, Aviv REIT, Inc., a Maryland corporation (“Aviv”), merged (the “Aviv Merger”) with and into a wholly owned subsidiary of Omega, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of October 30, 2014 (the “Merger Agreement”), by and among Omega, Aviv, OHI Healthcare Properties Holdco, Inc., a Delaware corporation (“OHI Holdco”), Omega OP, and Aviv Healthcare Properties Limited Partnership, a Delaware limited partnership. Prior to April 1, 2015 and in accordance with the Merger Agreement, Omega restructured the manner in which it holds its assets by converting to an umbrella partnership real estate investment trust structure (the “UPREIT Conversion”). As a result of the UPREIT Conversion and following the consummation of the Aviv Merger, all of Omega’s assets are held by Omega OP, through its equity interests in its subsidiaries. Omega OP is governed by the Second Amended and Restated Agreement of Limited Partnership of OHI Healthcare Properties Limited Partnership, dated as of April 1, 2015 (the “Partnership Agreement”). Omega is the sole general partner of Omega OP, and has exclusive control over Omega OP’s day-to-day management pursuant to the Partnership Agreement. As of September 30, 2017, Omega owned approximately 96% of the issued and outstanding units of partnership interest in Omega OP (“Omega OP Units”), and investors owned approximately 4% of the outstanding Omega OP Units. On September 26, 2017, OHI Holdco, a wholly owned subsidiary of Omega and a co-general partner of Omega OP, was merged with and into Omega, resulting in Omega becoming the sole general partner of Omega OP. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods reported herein are not necessarily indicative of results to be expected for the full year. These unaudited consolidated financial statements should be read in conjunction with the financial statements and the footnotes thereto included in our Form 10-K/A filed with the SEC on August 9, 2017. Omega’s consolidated financial statements include the accounts of (i) Omega, (ii) Omega OP, and (iii) all direct and indirect wholly owned subsidiaries of Omega. All intercompany transactions and balances have been eliminated in consolidation and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests. Omega OP’s consolidated financial statements include the accounts of (i) Omega OP, and (ii) all direct and indirect wholly owned subsidiaries of Omega OP. All intercompany transactions and balances have been eliminated in consolidation. Real Estate Investment Impairment Management evaluates our real estate investments for impairment indicators at each reporting period, including the evaluation of our assets’ useful lives. The judgment regarding the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance, legal structure, as well as our intent with respect to holding or disposing of the asset. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to the future undiscounted cash flows of the underlying facilities. The estimated future undiscounted cash flows are generally based on the related lease which relates to one or more properties. In cases where the Company decides to separate one or more properties from the related lease in anticipation of a sale or transition of the property to another operator, the estimated undiscounted future cash flows specific to those properties are separated from the related lease at that time. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows based on our intended use of the property are determined to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the real estate investments for the excess of carrying value over fair value. The fair value of the real estate investment is determined based on current market conditions and consider matters such as rental rates and occupancies for comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers or prospective purchasers. Additionally, our evaluation of fair value may consider valuing the property as a nursing home as well as alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset. Management’s impairment evaluation process, and when applicable, impairment calculations involve estimation of the future cash flows from management’s intended use of the property. Changes in the facts and circumstances that drive management’s assumptions may result in an impairment of the Company’s assets in a future period that could be material to the Company’s results of operations. For the three months ended September 30, 2017 and 2016, we recognized impairment losses on real estate properties of $17.8 million and $17.3 million, respectively. For the nine months ended September 30, 2017 and 2016, we recognized impairment losses on real estate properties of $35.6 million and $58.7 million, respectively. For additional information see Note 2 – Properties and Investments. Allowance for Losses on Mortgages, Other Investments and Direct Financing Leases The allowances for losses on mortgage notes receivable, other investments and direct financing leases (collectively, our “loans”) are maintained at a level believed adequate to absorb potential losses. The determination of the allowances is based on a quarterly evaluation of these loans, including general economic conditions and estimated collectability of loan payments. We evaluate the collectability of our loans receivable based on a combination of factors, including, but not limited to, delinquency status, financial strength of the borrower and guarantors and the value of the underlying collateral. If such factors indicate that there is greater risk of loan charge-offs, additional allowances or placement on non-accrual status may be required. A loan is impaired when, based on current information and events, it is probable that we will be unable to collect all amounts due as scheduled according to the contractual terms of the loan agreements. Consistent with this definition, all loans on non-accrual status are deemed impaired. To the extent circumstances improve and the risk of collectability is diminished, we will return these loans to full accrual status. When management identifies potential loan impairment indicators, the loan is written down to the present value of the expected future cash flows. In cases where expected future cash flows are not readily determinable, the loan is written down to the fair value of the underlying collateral. We may base our valuation on a loan’s observable market price, if any, or the fair value of collateral, net of sales costs, if the repayment of the loan is expected to be provided solely by the sale of the collateral. We account for impaired loans and direct financing leases using (a) the cost-recovery method, and/or (b) the cash basis method. We generally utilize the cost-recovery method for impaired loans or direct financing leases for which impairment reserves were recorded. We utilize the cash basis method for impaired loans or direct financing leases for which no impairment reserves were recorded because the net present value of the discounted cash flows expected under the loan or direct financing lease and/or the underlying collateral supporting the loan or direct financing lease were equal to or exceeded the book value of the loans or direct financing leases. Under the cost-recovery method, we apply cash received against the outstanding loan balance or direct financing lease prior to recording interest income. Under the cash basis method, we apply cash received to principal or interest income based on the terms of the agreement. As of September 30, 2017 and December 31, 2016, we had $181.8 million and $8.7 million, respectively, of reserves on our loans. For additional information see Note 3 – Direct Financing Leases, Note 4 – Mortgage Notes Receivable and Note 5 – Other Investments. Goodwill Impairment We assess goodwill for potential impairment during the fourth quarter of each fiscal year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the net assets of the reporting unit. In evaluating goodwill for impairment on an interim basis, we assess qualitative factors such as a current macroeconomic conditions, state of the equity and capital markets and our overall financial and operating performance Noncontrolling Interests Noncontrolling interests is the portion of equity not attributable to the respective reporting entity. We present the portion of any equity that we do not own in consolidated entities as noncontrolling interests and classify those interests as a component of total equity, separate from total stockholders’ equity, or owners’ equity on our Consolidated Balance Sheets. We include net (loss) income attributable to the noncontrolling interests in net income in our Consolidated Statements of Operations. As our ownership of a controlled subsidiary increases or decreases, any difference between the aggregate consideration paid to acquire the noncontrolling interests and our noncontrolling interest balance is recorded as a component of equity in additional paid-in capital, so long as we maintain a controlling ownership interest. The noncontrolling interest for Omega represents the outstanding Omega OP Units held by outside investors. Foreign Operations The U.S. dollar is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound. For our consolidated subsidiaries whose functional currency is not the U.S. dollar, we translate their financial statements into the U.S. dollar. We translate assets and liabilities at the exchange rate in effect as of the financial statement date. Revenue and expense accounts are translated using an average exchange rate for the period. Gains and losses resulting from translation are included in Omega OP’s owners’ equity and Omega’s accumulated other comprehensive loss (“AOCL”), as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interests. We and certain of our consolidated subsidiaries may have intercompany and third-party debt that is not denominated in the entity’s functional currency. When the debt is remeasured against the functional currency of the entity, a gain or loss can result. The resulting adjustment is reflected in results of operations, unless it is intercompany debt that is deemed to be long-term in nature and then the adjustments are included in Omega OP’s owners’ equity and Omega’s AOCL. Derivative Instruments Cash flow hedges During our normal course of business, we may use certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at the inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with the Company’s related assertions. The Company recognizes all derivative instruments, including embedded derivatives required to be bifurcated, as assets or liabilities in the Consolidated Balance Sheets at their fair value which are determined using a market approach and Level 2 inputs. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in earnings. For derivatives designated as qualifying cash flow hedging relationships, the change in fair value of the effective portion of the derivatives is recognized in Omega OP’s owners’ equity and Omega’s AOCL as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest, whereas the change in fair value of the ineffective portion is recognized in earnings. We formally document all relationships between hedging instruments and hedged items, as well as our risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific forecasted transactions as well as recognized obligations or assets in the Consolidated Balance Sheets. We also assess and document, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, we discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the current fair value of the derivative. As a matter of policy, we do not use derivatives for trading or speculative purposes. At September 30, 2017 and December 31, 2016, we had $1.2 million and $1.5 million, respectively, of qualifying cash flow hedges recorded at fair value in accrued expenses and other liabilities on our Consolidated Balance Sheets. Net investment hedge We use the spot method to measure the effectiveness of our net investment hedge. Under this method, for each reporting period, the change in the carrying value of the hedging instrument due to remeasurement of the effective portion is reported in Omega OP’s owners’ equity and Omega’s AOCL in our Consolidated Balance Sheets and the remaining change in the carrying value of the ineffective portion, if any, is recognized in earnings. We evaluate the effectiveness of our net investment hedge on a quarterly basis. We did not record any ineffectiveness for fiscal 2017. Accounts Receivable Accounts receivable includes: contractual receivables, effective yield interest receivables, straight-line rent receivables and lease inducements, net of an estimated provision for losses related to uncollectible and disputed accounts. Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line rent receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception or renewal of the lease, and are amortized as a reduction of rental revenue over the non-cancellable lease term. On a quarterly basis, we review our accounts receivable to determine their collectability. The determination of collectability of these assets requires significant judgment and is affected by several factors relating to the credit quality of our operators that we regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement environment, (iv) the ability of the tenant to perform under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying collateral of the agreement. If we determine collectability of any of our contractual receivables is at risk, we estimate the potential uncollectible amounts and provide an allowance. In the case of a lease recognized on a straight-line basis, a mortgage recognized on an effective yield basis or the existence of lease inducements, we generally provide an allowance for straight-line, effective interest, and/or lease inducement accounts receivable when certain conditions or indicators of adverse collectability are present. If the accounts receivable balance is subsequently deemed uncollectible, the receivable and allowance for doubtful account balance are written off. At September 30, 2017, three of our operators were approximately 90 days or more past due on rent/interest payments to the Company. Two of these operators are considered top ten operators as determined based on total revenue. Of these three operators, rent/interest from two of these operators is being recognized on a cash basis as of September 30, 2017. A summary of our accounts receivable by type is as follows: September 30, December 31, 2017 2016 (in thousands) Contractual receivables $ 42,085 $ 13,376 Effective yield interest receivables 11,307 9,749 Straight-line rent receivables 218,292 208,874 Lease inducements 7,051 8,393 Allowance for contractual receivables (8,989 ) (357 ) Accounts receivable – net $ 269,746 $ 240,035 During the third quarter of 2017, the Company recorded a provision for uncollectible accounts of approximately $9.5 million related to contractual and straight-line rent receivables for one of our top ten operators. See Note 3 – Direct Financing Leases for additional information. Related Party Transactions The Company has a policy which generally requires related party transactions to be approved or ratified by the Audit Committee. On February 1, 2016, we acquired 10 SNFs from Laurel Healthcare Holdings, Inc. (“Laurel”) for approximately $169.0 million in cash and leased them to an unrelated existing operator. A former member of the Board of Directors of the Company, together with certain members of his immediate family, beneficially owned approximately 34% of the equity of Laurel prior to the transaction. Immediately following our acquisition, the unrelated existing operator acquired all of the outstanding equity interests of Laurel, including the interests previously held by the former director of the Company and his family. Reclassification Certain prior quarter amounts have been reclassified to conform with the current quarter presentation. Accounting Pronouncement Adopted in 2017 In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Compensation-Stock Compensation (Topic 718) Recent Accounting Pronouncements - Pending Adoption In 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers Principal versus Agent Considerations (Reporting Revenue Gross versus Net), Identifying Performance Obligations and Licensing, Narrow-Scope Improvements and Practical Expedients. In February 2016, the FASB issued ASU 2016-02, Leases In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326 In August 2017 the FASB issued ASU 2017-12, Derivatives and Hedging: Targeted Improvements to Accounting for Hedging Activities

PROPERTIES AND INVESTMENTS

PROPERTIES AND INVESTMENTS	9 Months Ended
	Sep. 30, 2017
Real Estate [Abstract]
PROPERTIES AND INVESTMENTS	NOTE 2 – PROPERTIES AND INVESTMENTS Leased Property Our leased real estate properties, represented by 772 SNFs, 120 ALFs, 16 specialty facilities and one medical office building at September 30, 2017, are leased under provisions of single or master operating leases with initial terms typically ranging from five to 15 years, plus renewal options. Also see Note 3 – Direct Financing Leases for information regarding additional properties accounted for as direct financing leases. Substantially all of our leases contain provisions for specified annual increases over the rents of the prior year and are generally computed in one of three methods depending on specific provisions of each lease as follows: (i) a specific annual percentage increase over the prior year’s rent, generally between 2.0% and 3.0%; (ii) an increase based on the change in pre-determined formulas from year to year (e.g., increases in the Consumer Price Index (“CPI”)); or (iii) specific dollar increases over prior years. Under the terms of the leases, the lessee is responsible for all maintenance, repairs, taxes and insurance on the leased properties. A summary of our investment in leased real estate properties is as follows: September 30, December 31, 2017 2016 (in thousands) Buildings $ 6,249,790 $ 5,954,771 Land 818,014 759,295 Furniture, fixtures and equipment 471,495 454,760 Site improvements 225,455 206,206 Construction in progress 212,289 191,326 Total real estate investments 7,977,043 7,566,358 Less accumulated depreciation (1,432,154 ) (1,240,336 ) Real estate investments - net $ 6,544,889 $ 6,326,022 The following table summarizes the significant acquisitions that occurred in 2017: Number of Country/ Total Land Building & Site Improvements Furniture Initial (2) Period SNF ALF State (in millions) (%) Q1 - 1 VA $ 7.6 $ 0.5 $ 6.8 $ 0.3 7.50 Q2 1 - NC 8.6 0.7 7.3 0.6 9.50 Q2 - 18 UK 124.2 (1) 34.1 85.1 5.0 8.50 Q3 - 1 TX 2.3 0.7 1.5 0.1 9.25 Q3 15 - IN 211.0 18.0 180.2 12.8 9.50 Q3 9 - TX 19.0 (3) 1.7 15.5 1.8 18.60 Total 25 20 $ 372.7 $ 55.7 $ 296.4 $ 20.6 (1) Omega recorded a non-cash deferred tax liability and acquisition costs of approximately $8.2 million and $1.2 million, respectively, in connection with this acquisition. (2) The cash yield is based on the purchase price. (3) In July 2017, we transitioned nine SNFs formerly subject to a direct financing lease to another operator. As a result of terminating the direct financing lease, we wrote down the facilities to our original cost basis and recorded an impairment on the direct financing lease of approximately $1.8 million. See Note 3 – Direct Financing Leases for additional information. During the second quarter of 2017, we acquired two parcels of land which are not reflected in the table above for approximately $5.5 million with the intent of building new facilities for an existing operator. Asset Sales, Impairments and Other During the first quarter of 2017, we sold 15 facilities subject to operating leases for approximately $45.8 million in net proceeds recognizing a gain on sale of approximately $7.4 million. Eleven of the sold facilities were previously classified as held for sale. In addition, we recorded impairments of approximately $7.6 million on three facilities, one of which was reclassified to held for sale as of March 31, 2017. During the second quarter of 2017, we sold three facilities subject to operating leases for approximately $18.3 million in net cash proceeds recognizing a loss on sale of approximately $0.6 million. Two of the sold facilities were previously classified as assets held for sale. In addition, we recorded impairments of approximately $10.1 million on six facilities. During the third quarter of 2017, we sold two SNFs (one previously classified as held for sale) subject to operating leases for approximately $5.7 million in net proceeds recognizing a gain on sale of approximately $0.7 million. In addition, we recorded impairments of approximately $15.3 million on five facilities (two were subsequently reclassified to held for sale). We also wrote off approximately $2.5 million of capitalized costs associated with the termination of a construction project with one of our operators. Our recorded impairments were primarily the result of a decision to exit certain non-strategic facilities and/or operators. We reduced the net book value of the impaired facilities to their estimated fair values or, with respect to the facilities reclassified to held for sale, to its estimated fair value less costs to sell. To estimate the fair value of the facilities, we utilized a market approach and Level 3 inputs (which generally consist of non-binding offers from unrelated third parties). Also see Note 3 – Direct Financing Leases and Note 7 – Assets Held For Sale.

DIRECT FINANCING LEASES

DIRECT FINANCING LEASES	9 Months Ended
	Sep. 30, 2017
DIRECT FINANCING LEASES - MINIMUM RENTS
DIRECT FINANCING LEASES	NOTE 3 – DIRECT FINANCING LEASES The components of investments in direct financing leases consist of the following: September 30, December 31, 2017 2016 (in thousands) Minimum lease payments receivable $ 3,716,562 $ 4,287,069 Less unearned income (3,179,625 ) (3,685,131 ) Investment in direct financing leases 536,937 601,938 Less allowance for loss on direct financing lease (171,940 ) — Investment in direct financing leases – net $ 364,997 $ 601,938 Properties subject to direct financing leases 42 58 The following minimum rents are due under our direct financing leases for the remainder of 2017 and the subsequent five years (in thousands): 2017 (1) 2018 (1) 2019 (1) 2020 (1) 2021 (1) 2022 (1) $ 11,245 $ 45,798 $ 46,920 $ 48,059 $ 49,136 $ 50,349 (1) Orianna represents approximately 94% of the contractual minimum rent payments due under our direct financing leases. On November 27, 2013, we closed an aggregate $529 million purchase/leaseback transaction in connection with the acquisition of Ark Holding Company, Inc. (“Ark Holding”) by 4 West Holdings Inc. At closing, we acquired 55 SNFs and 1 ALF operated by Ark Holding and leased the facilities back to Ark Holding, now known as New Ark Investment Inc. (“New Ark” which does business as “Orianna Health Systems” and is herein referred to as “Orianna”), pursuant to four 50-year master leases with rental payments yielding 10.6% per annum over the term of the leases. The purchase/leaseback transaction is being accounted for as a direct financing lease. The lease agreements allow the tenant the right to purchase the facilities for a bargain purchase price plus closing costs at the end of the lease term. In addition, commencing in the 41st year of each lease, the tenant will have the right to prepay the remainder of its obligations thereunder for an amount equal to the sum of the unamortized portion of the original aggregate $529 million investment plus the net present value of the remaining payments under the lease and closing costs. In the event the tenant exercises either of these options, we have the right to purchase the properties for fair value at the time. In March 2017, we executed sale agreements with two unrelated third parties to sell seven facilities leased to Orianna located in the Northwest, representing all of the facilities subject to that direct financing lease, with a carrying value of approximately $36.4 million for approximately $34.0 million. During the first quarter of 2017, we recorded an impairment of approximately $2.4 million. In the second quarter of 2017, we sold five of the Northwest facilities and received net cash proceeds of approximately $27.3 million and recorded an additional impairment of approximately $0.9 million. In the third quarter of 2017, we sold the remaining two Northwest facilities for approximately $5.8 million. In July 2017, we transitioned nine SNFs, representing all of the facilities subject to another direct financing lease with Orianna in the Texas region, to an existing operator of the Company pursuant to an operating lease. In connection with this transaction, we recorded the real estate properties at our original cost basis of approximately $19.0 million, eliminated our investment in the direct financing lease and recorded an impairment of approximately $1.8 million. In conjunction with this transaction, we also amended our Orianna Southeast region master lease in July 2017 to reduce the outstanding balance by $19.3 million. As a result of the amendment, we recorded an impairment on our investment in direct financing lease of approximately $20.8 million in the third quarter of 2017. Orianna has not satisfied the contractual payments due under the terms of the remaining two direct financing leases or the separate operating lease with the Company and the collectability of future amounts due is uncertain. The Company is in preliminary discussions with Orianna regarding future actions. Such actions may include a) the sale of some or all of the facilities, b) transitioning some or all of the facilities from Orianna to other operators and c) pursuing legal action to enforce the terms of the existing agreements. During the third quarter of 2017, the Company recorded an allowance for loss of $171.9 million with Orianna covering 38 facilities in the Southeast region of the U.S. The amount of the allowance was determined based on the fair value of the facilities subject to the direct financing lease. To estimate the fair value of the underlying collateral, the Company utilized an income approach and Level 3 inputs. The Company considered current and projected operating performance of the facilities, projected rent, prevailing capitalization rates and coverages and bed values. Such assumptions are subject to change based on changes in market conditions and the ultimate resolution of this matter. Such changes could be significantly different than the currently estimated fair value and such differences could have a material impact on the Company’s financial statements. The 39 facilities under our master leases with Orianna as of September 30, 2017 are located in seven states, predominantly in the southeastern U.S. (38 facilities) and Indiana (1 facility). Our recorded investment in these direct financing leases, net of the $171.9 million allowance, amounted to $337.7 million, as of September 30, 2017. For the three months ended September 30, 2017, we did not recognize any direct financing lease income from Orianna. We recognized total impairments on direct financing leases for the three and nine months ended September 30, 2017 of $194.7 million and $198.0 million, respectively. Additionally, we own four facilities and lease them to Orianna under a master lease which expires in 2026. The four facility lease is being accounted for as an operating lease. We did not recognize any income on this operating lease in the third quarter of 2017 as Orianna did not pay the contractual amounts due and collectability is uncertain. Our recorded investment in this operating lease was $38.9 million as of September 30, 2017. As of September 30, 2017, we have an allowance for contractual receivables and straight-line rent receivables related to this lease of $1.9 million representing all amounts due.

MORTGAGE NOTES RECEIVABLE

MORTGAGE NOTES RECEIVABLE	9 Months Ended
	Sep. 30, 2017
Mortgage Notes Receivable Investments [Abstract]
MORTGAGE NOTES RECEIVABLE	NOTE 4 – MORTGAGE NOTES RECEIVABLE As of September 30, 2017, mortgage notes receivable relate to 29 fixed rate mortgages on 52 long-term care facilities. The mortgage notes are secured by first mortgage liens on the borrowers' underlying real estate and personal property. The mortgage notes receivable relate to facilities located in ten states that are operated by seven independent healthcare operating companies. We monitor compliance with mortgages and when necessary have initiated collection, foreclosure and other proceedings with respect to certain outstanding mortgage notes. Mortgage interest income is recognized as earned over the terms of the related mortgage notes, using the effective yield method. Allowances are provided against earned revenues from mortgage interest when collection of amounts due becomes questionable or when negotiations for restructurings of troubled operators lead to lower expectations regarding ultimate collection. When collection is uncertain, mortgage interest income on impaired mortgage loans is recognized as received after taking into account the application of security deposits. The outstanding principal amounts of mortgage notes receivable, net of allowances, were as follows: September 30, December 31, 2017 2016 (in thousands) Mortgage note due 2024; interest at 9.98% $ 112,500 $ 112,500 Mortgage note due 2029; interest at 9.68% 411,119 412,140 Other mortgage notes outstanding (1) 147,734 118,637 Mortgage notes receivable, gross 671,353 643,277 Allowance for loss on mortgage notes receivable (4,747 ) (3,934 ) Total mortgages — net $ 666,606 $ 639,343 (1) Other mortgage notes outstanding have stated interest rates ranging from 8.35% to 14.0% and maturity dates through 2029.

OTHER INVESTMENTS

OTHER INVESTMENTS	9 Months Ended
	Sep. 30, 2017
Receivables [Abstract]
OTHER INVESTMENTS	NOTE 5 – OTHER INVESTMENTS A summary of our other investments is as follows: September 30, December 31, 2017 2016 (in thousands) Other investment note due 2019; interest at 10.99% $ 49,646 $ 49,458 Other investment note due 2020; interest at 14.43% 47,841 47,913 Other investment note due 2022, interest at 9.00% 31,987 31,987 Other investment note due 2030; interest at 6.66% 50,000 44,595 Other investment notes outstanding (1) 99,362 87,691 Other investments, gross 278,836 261,644 Allowance for loss on other investments (5,015 ) (4,798 ) Total other investments $ 273,821 $ 256,846 (1) Other investment notes have maturity dates through 2028 and interest rates ranging from 6.50% to 12.0%. Other investment notes settlement In August 2017, we executed an agreement with an existing operator that terminated our purchase option buyout obligation of approximately $30.7 million. The purchase option buyout obligation was recorded in accrued expenses and other liabilities on our Consolidated Balance Sheets. In exchange, we agreed to the settlement of other investments notes with a weighted average interest rate of 10.5% and a carrying value of approximately $30.2 million.

INVESTMENT IN UNCONSOLIDATED JO

INVESTMENT IN UNCONSOLIDATED JOINT VENTURE	9 Months Ended
	Sep. 30, 2017
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENT IN UNCONSOLIDATED JOINT VENTURE	NOTE 6 – INVESTMENT IN UNCONSOLIDATED JOINT VENTURE On November 1, 2016, we invested approximately $50.0 million for an approximate 15% ownership interest in a joint venture operating as Second Spring Healthcare Investments. The other approximate 85% interest is owned by affiliates of Lindsey Goldberg LLC. We account for the joint venture using the equity method. On November 1, 2016, the joint venture acquired 64 SNFs from Welltower Inc. for approximately $1.1 billion and leased them to a single operator. We receive asset management fees from the joint venture for services provided. For the three and nine months ended September 30, 2017, we recognized $0.5 million and $1.5 million, respectively, of asset management fees. These fees are included in miscellaneous income in the accompanying Consolidated Statements of Operations. The accounting policies for the unconsolidated joint venture are the same as those of the Company.

ASSETS HELD FOR SALE

ASSETS HELD FOR SALE	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]
ASSETS HELD FOR SALE	NOTE 7 – ASSETS HELD FOR SALE The following is a summary of our assets held for sale: Properties Held For Sale Number of Net Book Value December 31, 2016 20 $ 52,868 Properties sold/other (1) (12 ) (30,023 ) Properties added (2) 1 400 March 31, 2017 9 $ 23,245 Properties sold/other (1) (2 ) (4,356 ) June 30, 2017 7 $ 18,889 Properties sold/other (1) (1 ) (3,075 ) Properties added (2) 2 1,510 September 30, 2017 (3) 8 $ 17,324 (1) In the first quarter of 2017, we sold nine SNFs and two ALFs for approximately $29.4 million in net proceeds recognizing a gain on sale of approximately $3.6 million. One SNF classified as an asset held for sale at December 31, 2016 was no longer considered held for sale during the first quarter of 2017 and was reclassified back to leased properties at approximately $5.1 million which represents the facility’s then carrying value adjusted for depreciation that was not recognized while classified as held for sale. In the second quarter of 2017, we sold one ALF and one SNF for approximately $5.0 million in net proceeds, generating a gain on sale of approximately $0.6 million. In the third quarter of 2017, we sold one SNF for approximately $3.1 million in net proceeds recognizing a gain of $0.3 million. (2) In the first quarter of 2017, we recorded a $3.5 million impairment to reduce one ALF’s net book value to its estimated fair value less costs to sell before it was reclassified to assets held for sale. In the third quarter of 2017, we recorded a $4.5 million impairment to reduce two SNFs to their estimated fair value less costs to sell before they were reclassified to assets held for sale. (3) We plan to sell the facilities classified as held for sale at September 30, 2017 within the next twelve months.

INTANGIBLES

INTANGIBLES	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLES	NOTE 8 – INTANGIBLES The following is a summary of our intangibles as of September 30, 2017 and December 31, 2016 September 30, December 31, 2017 2016 (in thousands) Assets: Goodwill $ 644,571 $ 643,474 Above market leases $ 22,426 $ 22,476 In-place leases 167 167 Accumulated amortization (16,791 ) (15,864 ) Net intangible assets $ 5,802 $ 6,779 Liabilities: Below market leases $ 164,443 $ 165,028 Accumulated amortization (80,747 ) (70,738 ) Net intangible liabilities $ 83,696 $ 94,290 Above market leases and in-place leases, net of accumulated amortization, are included in other assets on our Consolidated Balance Sheets. Below market leases, net of accumulated amortization, are included in accrued expenses and other liabilities on our Consolidated Balance Sheets. The net amortization related to the above and below market leases is included in our Consolidated Statements of Operations as an adjustment to rental income. For the three months ended September 30, 2017 and 2016, our net amortization related to intangibles was $2.9 million and $3.0 million, respectively. For the nine months ended September 30, 2017 and 2016, our net amortization related to intangibles was $9.1 million and $11.0 million, respectively. The estimated net amortization related to these intangibles for the remainder of 2017 and the subsequent four years is as follows: remainder of 2017 – $2.8 million; 2018 – $10.5 million; 2019 – $9.4 million; 2020 – $9.2 million and 2021 – $8.6 million. As of September 30, 2017 the weighted average remaining amortization period of above market leases (inclusive of in-place leases) and below market leases is approximately eight years and nine years, respectively. The following is a reconciliation of our goodwill as of September 30, 2017: (in thousands) Balance as of December 31, 2016 $ 643,474 Add: foreign currency translation 1,097 Balance as of September 30, 2017 $ 644,571

CONCENTRATION OF RISK

CONCENTRATION OF RISK	9 Months Ended
	Sep. 30, 2017
Risks and Uncertainties [Abstract]
CONCENTRATION OF RISK	NOTE 9 – CONCENTRATION OF RISK As of September 30, 2017, our portfolio of real estate investments consisted of 1,012 healthcare facilities, located in 42 states and the U.K. and operated by 77 third party operators. Our investment in these facilities, net of impairments and reserve for uncollectible loans, totaled approximately $9.0 billion at September 30, 2017, with approximately 99% of our real estate investments related to long-term care facilities. Our portfolio is made up of 813 SNFs, 121 ALFs, 16 specialty facilities, one medical office building, fixed rate mortgages on 47 SNFs and four ALFs, and ten facilities that are closed/held-for-sale. At September 30, 2017, we also held other investments of approximately $273.8 million, consisting primarily of secured loans to third-party operators of our facilities and a $37.7 million investment in an unconsolidated joint venture. At September 30, 2017, we had investments with one operator/or manager that exceeded 10% of our total investments: Ciena Healthcare (“Ciena”). Ciena generated 11% of our total revenues for the three months ended September 30, 2017 and 10% of our total revenues for the nine months ended September 30, 2017. At September 30, 2017, the three states in which we had our highest concentration of investments were Ohio (9%), Florida (9%) and Texas (8%).

STOCKHOLDERS'_OWNERS' EQUITY

STOCKHOLDERS'/OWNERS' EQUITY	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
STOCKHOLDERS'/OWNERS' EQUITY	NOTE 10 – STOCKHOLDERS’/OWNERS' EQUITY The Board of Directors has declared common stock dividends as set forth below: Record Date Payment Date Dividend per Increase over January 31, 2017 February 15, 2017 $ 0.62 $ 0.01 May 1, 2017 May 15, 2017 0.63 0.01 August 1, 2017 August 15, 2017 0.64 0.01 October 31, 2017 November 15, 2017 0.65 0.01 On the same dates listed above, Omega OP Unit holders received the same distributions per unit as those paid to the common stockholders of Omega. $500 Million Equity Shelf Program For the three months ended September 30, 2017, we issued 0.5 million shares of our common stock at an average price of $31.73 per share, net of issuance costs, generating net proceeds of $15.6 million under our $500 million Equity Shelf Program. For the nine months ended September 30, 2017, we issued 0.7 million shares of our common stock at an average price of $30.92 per share, net of issuance costs, generating net proceeds of $22.2 million under our $500 million Equity Shelf Program. Dividend Reinvestment and Common Stock Purchase Plan For the three months ended September 30, 2017, approximately 0.3 million shares of our common stock at an average price of $30.39 per share were issued through our Dividend Reinvestment and Common Stock Purchase Program for gross proceeds of approximately $10.4 million. For the nine months ended September 30, 2017, approximately 1.0 million shares of our common stock at an average price of $31.49 per share were issued through our Dividend Reinvestment and Common Stock Purchase Program for gross proceeds of approximately $30.1 million. Accumulated Other Comprehensive Loss The following is a summary of our accumulated other comprehensive loss, net of tax where applicable: As of and For the Three Months Ended September 30, As of and For the Nine Months Ended September 30, 2017 2016 2017 2016 (in thousands) Foreign Currency Translation: Beginning balance $ (40,340 ) $ (34,979 ) $ (54,948 ) $ (8,413 ) Translation gain (loss) 10,870 (6,623 ) 25,338 (33,167 ) Realized gain (loss) 95 (222 ) 235 (244 ) Ending balance (29,375 ) (41,824 ) (29,375 ) (41,824 ) Derivative Instruments: Cash flow hedges: Beginning balance (1,380 ) (13,792 ) (1,420 ) (718 ) Unrealized loss (gain) (332 ) 980 (1,682 ) (12,094 ) Realized gain (1) 490 - 1,880 - Ending balance (1,222 ) (12,812 ) (1,222 ) (12,812 ) Net investment hedge: Beginning balance (2,193 ) - - - Unrealized loss (3,750 ) - (5,943 ) - Ending balance (5,943 ) - (5,943 ) - Total accumulated other comprehensive loss for Omega OP (2) (36,540 ) (54,636 ) (36,540 ) (54,636 ) Add: portion included in noncontrolling interest 1,697 2,466 1,697 2,466 Total accumulated other comprehensive loss for Omega $ (34,843 ) $ (52,170 ) $ (34,843 ) $ (52,170 ) (1) Recorded in interest expense on the Consolidated Statements of Operations. (2) These amounts are included in owners’ equity.

TAXES

TAXES	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
TAXES	NOTE 11 – TAXES Omega is a REIT for United States federal income tax purposes, and Omega OP is a pass through entity for United States federal income tax purposes. Since our inception, Omega has elected to be taxed as a REIT under the applicable provisions of the Internal Revenue Code (“Code”). A REIT is generally not subject to federal income tax on that portion of its REIT taxable income which is distributed to its stockholders, provided that at least 90% of such taxable income is distributed each tax year and certain other requirements are met, including asset and income tests. So long as we qualify as a REIT under the Code, we generally will not be subject to federal income taxes on the REIT taxable income that we distribute to stockholders, subject to certain exceptions. If the Company fails to qualify as a REIT in any taxable year, the Company will be subject to federal income taxes on its taxable income at regular corporate rates and dividends paid to our stockholders will not be deductible by us in computing taxable income. Further, we will not be permitted to qualify for treatment as a REIT for federal income tax purposes for four years following the year in which qualification is denied, unless the Internal Revenue Service grants us relief under certain statutory provisions. Failing to qualify as a REIT could materially and adversely affect the Company’s net income; however, we believe we are organized and operate in such a manner as to qualify for treatment as a REIT. We test our compliance within the REIT taxation rules to ensure that we are in compliance with the REIT rules on a quarterly and annual basis. We review our distributions and projected distributions each year to ensure we have met and will continue to meet the annual REIT distribution requirements. In 2017, we expect to distribute dividends in excess of our taxable income. As a result of our UPREIT Conversion, our Company and its subsidiaries may be subject to income or franchise taxes in certain states and municipalities. Also, as a result of our UPREIT Conversion, we created five wholly owned subsidiary REITs and added a sixth wholly owned subsidiary REIT as of January 1, 2016, all of which are subject to all of the REIT qualification rules set forth in the Code. We merged five of the wholly owned subsidiary REITs into a single wholly owned subsidiary REIT in December 2015, and then merged the sixth wholly owned subsidiary REIT into our other wholly owned subsidiary REIT in December 2016, which wholly owned subsidiary REIT remains subject to all of the REIT qualification rules set forth in the Code. Subject to the limitation under the REIT asset test rules, we are permitted to own up to 100% of the stock of one or more taxable REIT subsidiaries (“TRSs”). We have elected for two of our active subsidiaries to be treated as TRSs. One of our TRSs is subject to federal, state and local income taxes at the applicable corporate rates and the other is subject to foreign income taxes. As of September 30, 2017, our TRS that is subject to federal, state and local income taxes at the applicable corporate rates had a net operating loss carry-forward of approximately $0.7 million. The loss carry-forward is fully reserved as of September 30, 2017, with a valuation allowance due to uncertainties regarding realization. During the third quarter of 2017, we recorded approximately $0.7 million of state and local income tax provision and approximately $0.3 million of tax provision for foreign income taxes. For the nine months ended September 30, 2017, we recorded approximately $2.2 million of state and local income tax provision and approximately $0.5 million of tax provision for foreign income taxes. The expenses were included in provision for income taxes on our Consolidated Statements of Operations.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2017
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
STOCK-BASED COMPENSATION	NOTE 12 – STOCK-BASED COMPENSATION The following is a summary of our stock-based compensation expense for the three and nine months ended September 30, 2017 and 2016, respectively: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 (in thousands) Stock-based compensation expense $ 3,872 $ 3,673 $ 11,350 $ 10,116 Restricted Stock and Restricted Stock Units Restricted stock and restricted stock units (“RSUs”) are subject to forfeiture if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change in control of the Company. Prior to vesting, ownership of the shares/units cannot be transferred. Restricted stock has the same dividend and voting rights as our common stock. RSUs accrue dividend equivalents but have no voting rights. Restricted stock and RSUs are valued at the price of our common stock on the date of grant. We expense the cost of these awards ratably over their vesting period. We awarded 140,416 RSUs to employees on January 1, 2017. Performance Restricted Stock Units and LTIP Units Performance restricted stock units (“PRSUs”) and long term incentive plan units (“LTIP Units”) are subject to forfeiture if the performance requirements are not achieved or if the holder’s service to us terminates prior to vesting, subject to certain exceptions for certain qualifying terminations of employment or a change in control of the Company. The PRSUs and the LTIP Units have varying degrees of performance requirements to be earned and vested, and each PRSU and LTIP Units award represents the right to a variable number of shares of common stock or partnership units. Each LTIP Unit once earned and vested is convertible into one Omega OP Unit in Omega OP, subject to certain conditions. The earning requirements are based on either the (i) total shareholder return (“TSR”) of Omega or (ii) Omega’s TSR relative to other real estate investment trusts in the MSCI U.S. REIT Index or FTSE NAREIT Equity Health Care Index TSR (both “Relative TSR”). Vesting in general requires that the employee remain employed by us until the date specified in the applicable PRSU or LTIP agreement, which may be later than the date that the TSR or Relative TSR requirements are satisfied. We expense the cost of these awards ratably over their service period. Prior to vesting and the distribution of shares, ownership of the PRSUs cannot be transferred. Dividend equivalents on the PRSUs accumulate and with respect to PRSUs granted before 2015 are paid when the PRSUs vest and with respect to PRSUs granted in 2015 or later are paid once the PRSUs are earned. While each LTIP Unit is unearned, the employee receives a partnership distribution equal to 10% of the quarterly approved regular periodic distributions per Omega OP Unit. The remaining partnership distributions (which in the case of normal periodic distributions is equal to the total approved quarterly dividend on Omega’s common stock) on the LTIP Units accumulate, and if the LTIP Units are earned, the accumulated distributions are paid. The number of shares or units earned under the TSR PRSUs or LTIP Units depends generally on the level of achievement of Omega’s TSR over the indicated performance period. We awarded 399,726 LTIP Units to employees on January 1, 2017. The number of shares earned under the Relative TSR PRSUs depends generally on the level of achievement of Omega’s TSR relative to other real estate investment trusts in the MSCI U.S. REIT Index or FTSE NAREIT Equity Health Care Index TSR over the performance period indicated. We awarded 285,338 Relative TSR PRSUs to employees on January 1, 2017. The following table summarizes our total unrecognized compensation cost as of September 30, 2017 associated with restricted stock, restricted stock units, PRSU awards, and LTIP Unit awards to employees: Grant Shares/ Units Grant Date Total Compensation Cost (in millions) (1) Weighted Unrecognized Performance Vesting RSUs 3/31/15 RSU 2015 109,985 $ 40.57 $ 4.5 33 $ 0.4 N/A 12/31/2017 4/1/15 RSU 2015 40,464 40.74 1.6 33 0.2 N/A 12/31/2017 Assumed Aviv RSU 2015 7,799 35.08 0.3 33 - N/A 11/1/2017 3/17/16 RSU 2016 130,006 34.78 4.6 33 2.0 N/A 12/31/2018 1/1/2017 RSU 2017 140,416 31.26 4.3 36 3.3 N/A 12/31/2019 Restricted Stock Units Total 428,670 $ 35.68 $ 15.3 $ 5.9 TSR PRSUs and LTIP Units 2016 TSR 2014 135,634 $ 8.67 $ 1.2 48 $ 0.1 1/1/2014-12/31/2016 Quarterly in 2017 3/31/15 2017 LTIP Units 2015 137,249 14.66 2.0 45 0.7 1/1/2015-12/31/2017 Quarterly in 2018 4/1/2015 2017 LTIP Units 2015 53,387 14.81 0.8 45 0.2 1/1/2015-12/31/2017 Quarterly in 2018 3/17/2016 2018 LTIP Units 2016 370,152 13.21 4.9 45 2.9 1/1/2016-12/31/2018 Quarterly in 2019 1/1/2017 2019 LTIP Units 2017 399,726 12.61 5.0 48 4.1 1/1/2017-12/31/2019 Quarterly in 2020 TSR PRSUs & LTIP Total 1,096,148 $ 12.69 $ 13.9 $ 8.0 Relative TSR PRSUs 2016 Relative TSR 2014 135,634 $ 14.24 $ 1.9 48 $ 0.1 1/1/2014-12/31/2016 Quarterly in 2017 3/31/15 2017 Relative TSR 2015 137,249 22.50 3.1 45 1.0 1/1/2015-12/31/2017 Quarterly in 2018 4/1/2015 2017 Relative TSR 2015 53,387 22.92 1.2 45 0.4 1/1/2015-12/31/2017 Quarterly in 2018 3/17/2016 2018 Relative TSR 2016 305,563 16.44 5.1 45 2.9 1/1/2016-12/31/2018 Quarterly in 2019 1/1/2017 2019 Relative TSR 2017 285,338 18.04 5.1 48 4.2 1/1/2017-12/31/2019 Quarterly in 2020 Relative TSR PRSUs Total 917,171 $ 17.90 $ 16.4 $ 8.6 Grand Total 2,441,989 $ 18.68 $ 45.6 $ 22.5 (1) Total compensation costs are net of shares cancelled. Director Restricted Stock Grants As of September 30, 2017, we had 69,087 shares of restricted stock outstanding to directors. The outstanding restricted stock granted to directors prior to 2017 is in general scheduled to vest ratably over three years from the date of grant. Beginning with the 2017 grants, director restricted stock grants in general fully vest at the annual meeting following the grant date. As of September 30, 2017, the unrecognized compensation cost associated with outstanding director restricted stock grants is approximately $1.7 million.

BORROWING ACTIVITIES AND ARRANG

BORROWING ACTIVITIES AND ARRANGEMENTS	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
BORROWING ACTIVITIES AND ARRANGEMENTS	NOTE 13 – BORROWING ACTIVITIES AND ARRANGEMENTS Secured and Unsecured Borrowings The following is a summary of our borrowings: Annual Interest September 30, September 30, December 31, Maturity 2017 2017 2016 (in thousands) Secured borrowings: HUD mortgages assumed December 2011 (1) 2044 3.06 % $ 53,992 $ 54,954 Deferred financing costs – net (573 ) (589 ) Total secured borrowings – net (2) 53,419 54,365 Unsecured borrowings: Revolving line of credit 2021 2.49 % 365,000 190,000 Tranche A-1 term loan - - — 200,000 Tranche A-2 term loan - - — 200,000 Tranche A-3 term loan - - — 350,000 U.S. term loan 2022 2.69 % 425,000 — Sterling term loan 2022 1.70 % 133,980 — Omega OP term loan (2) 2022 2.69 % 100,000 100,000 2015 term loan 2022 3.80 % 250,000 250,000 Discounts and deferred financing costs – net (3) (5,759 ) (5,657 ) Total term loans – net 903,221 1,094,343 2023 notes 2023 4.375 % 700,000 700,000 2024 notes 2024 5.875 % — 400,000 2024 notes 2024 4.95 % 400,000 400,000 2025 notes 2025 4.50 % 400,000 250,000 2026 notes 2026 5.25 % 600,000 600,000 2027 notes 2027 4.50 % 700,000 700,000 2028 notes 2028 4.75 % 550,000 — Other 2018 - 1,500 3,000 Subordinated debt 2021 9.00 % 20,000 20,000 Discount - net (21,709 ) (17,151 ) Deferred financing costs – net (26,903 ) (27,703 ) Total unsecured borrowings – net 3,322,888 3,028,146 Total secured and unsecured borrowings – net $ 4,644,528 $ 4,366,854 (1) Reflects the weighted average annual contractual interest rate on the mortgages at September 30, 2017 excluding a third-party administration fee of approximately 0.5% annually. Secured by real estate assets with a net carrying value of $62.9 million as of September 30, 2017. (2) These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP. (3) This amount includes $0.6 million of net deferred financing costs related to the Omega OP term loan as of September 30, 2017. Certain of our other secured and unsecured borrowings are subject to customary affirmative and negative covenants, including financial covenants. As of September 30, 2017 and December 31, 2016, we were in compliance with all affirmative and negative covenants, including financial covenants, for our secured and unsecured borrowings. Omega OP, the guarantor of Parent’s outstanding senior notes, does not directly own any substantive assets other than its interest in non-guarantor subsidiaries. New and Amended Unsecured Credit Facility – 2017 2017 Omega Credit Facilities On May 25, 2017, Omega entered into a credit agreement (the “2017 Omega Credit Agreement”) providing us with a new $1.8 billion senior unsecured revolving and term loan credit facility, consisting of a $1.25 billion senior unsecured multicurrency revolving credit facility (the “Revolving Credit Facility”), a $425 million senior unsecured U.S. Dollar term loan facility (the “U.S. Term Loan Facility”), and a £100 million senior unsecured British Pound Sterling term loan facility (the “Sterling Term Loan Facility” and, together with the Revolving Credit Facility and the U.S. Term Loan Facility, collectively, the “2017 Omega Credit Facilities”). The 2017 Omega Credit Agreement contains an accordion feature permitting us, subject to compliance with customary conditions, to increase the maximum aggregate commitments under the 2017 Omega Credit Facilities to $2.5 billion. The 2017 Omega Credit Facilities replace the previous $1.25 billion senior unsecured 2014 revolving credit facility, the previous $200 million Tranche A-1 senior unsecured term loan facility, and the previous $350 million Tranche A-3 senior unsecured incremental term loan facility established under our 2014 credit agreement, which has been terminated (the “2014 Omega Credit Agreement”). We had previously repaid and terminated the $200 million Tranche A-2 senior unsecured term loan facility established under the 2014 Omega Credit Agreement, with proceeds from our $550 million and $150 million unsecured senior notes issued in April 2017. The Revolving Credit Facility bears interest at LIBOR plus an applicable percentage (with a range of 100 to 195 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Revolving Credit Facility matures on May 25, 2021, subject to an option by us to extend such maturity date for two, six month periods. The 2017 Omega Credit Agreement provides for the Revolving Credit Facility to be drawn in Euros, British Pounds Sterling, Canadian Dollars (collectively, “Alternative Currencies”) or U.S. Dollars, with a $900 million tranche available in U.S. Dollars and a $350 million tranche available in U.S. Dollars or Alternative Currencies. For purposes of the 2017 Omega Credit Facilities, references to LIBOR include the Canadian dealer offered rates for amounts offered in Canadian Dollars and any other Alternative Currency rate approved in accordance with the terms of the 2017 Omega Credit Agreement for amounts offered in any other non-London interbank offered rate quoted currency, as applicable. The U.S. Term Loan Facility and the Sterling Term Loan Facility bear interest at LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The U.S. Term Loan Facility and the Sterling Term Loan Facility each mature on May 25, 2022. For the three month period ending June 30, 2017, we recorded a non-cash charge of approximately $5.5 million relating to the write-off of deferred financing costs associated with the termination of the 2014 Omega Credit Facilities. Amended 2015 Term Loan Facility On May 25, 2017, Omega entered into an amended and restated credit agreement (the “Amended 2015 Credit Agreement”), which amended and restated our previous $250 million senior unsecured term loan facility (the “Amended 2015 Term Loan Facility”). The Amended 2015 Term Loan Facility bears interest at LIBOR plus an applicable percentage (with a range of 140 to 235 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The Amended 2015 Term Loan Facility continues to mature on December 16, 2022. The Amended 2015 Credit Agreement permits us, subject to compliance with customary conditions, to add one or more incremental tranches to the Amended 2015 Term Loan Facility in an aggregate principal amount not exceeding $150 million. Omega’s obligations under the 2017 Omega Credit Facilities and the Amended 2015 Term Loan Facility are jointly and severally guaranteed by Omega OP and any domestic subsidiary of Omega that provides a guaranty of any unsecured indebtedness of Omega for borrowed money evidenced by bonds, debentures, notes or other similar instruments in an amount of at least $50 million individually or in the aggregate. 2017 Omega OP Term Loan Facility On May 25, 2017, Omega OP entered into a credit agreement (the “2017 Omega OP Credit Agreement”) providing it with a new $100 million senior unsecured term loan facility (the “2017 Omega OP Term Loan Facility”). The 2017 Omega OP Credit Agreement replaces the $100 million senior unsecured term loan facility obtained in 2015 (the “2015 Omega OP Term Loan Facility”) and the related credit agreement (the “2015 Omega OP Credit Agreement”). The 2017 Omega OP Term Loan Facility bears interest at LIBOR plus an applicable percentage (with a range of 90 to 190 basis points) based on our ratings from Standard & Poor’s, Moody’s and/or Fitch Ratings. The 2017 Omega OP Term Loan Facility matures on May 25, 2022. Omega OP’s obligations in connection with the 2017 Omega OP Term Loan Facility are not currently guaranteed, but will be jointly and severally guaranteed by any domestic subsidiary of Omega OP that provides a guaranty of any unsecured indebtedness of Omega or Omega OP for borrowed money evidenced by bonds, debentures, notes or other similar instruments in an amount of at least $50 million individually or in the aggregate. $550 Million 4.75% Senior Notes and $150 Million 4.5% Senior Notes On April 4, 2017, Omega issued (i) $550 million aggregate principal amount of our 4.75% Senior Notes due 2028 (the “2028 Notes”) and (ii) an additional $150 million aggregate principal amount of our existing 4.50% Senior Notes due 2025 (the “2025 Notes”, and together with the 2028 Notes collectively, the “Notes”). The 2028 Notes mature on January 15, 2028 and the 2025 Notes mature on January 15, 2025. The 2028 Notes were sold at an issue price of 98.978% of their face value before the underwriters’ discount and the 2025 Notes were sold at an issue price of 99.540% of their face value before the underwriters’ discount. Our net proceeds from the Notes offering, after deducting underwriting discounts and expenses, were approximately $690.7 million. The net proceeds from the Notes offering were used to (i) redeem all of our outstanding $400 million aggregate principal amount of 5.875% Senior Notes due 2024 (the “5.875% Notes”) on April 28, 2017, (ii) prepay the $200 million Tranche A-2 Term Loan Facility on April 5, 2017 that otherwise would have become due on June 27, 2017, and (iii) repay outstanding borrowings under our revolving credit facility. $400 Million 5.875% Senior Notes Redemption On April 28, 2017, Omega redeemed all of our outstanding 5.875% Notes. As a result of the redemption, during the second quarter of 2017, we recorded approximately $16.5 million in redemption related costs and write-offs, including $11.8 million for the call premium and $4.7 million in net write-offs associated with unamortized deferred financing costs.

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
FINANCIAL INSTRUMENTS	NOTE 14 – FINANCIAL INSTRUMENTS The carrying amount of cash and cash equivalents, restricted cash and contractual receivables reported in the Consolidated Balance Sheets approximates fair value because of the short maturity of these instruments (Level 1). At September 30, 2017 and December 31, 2016, the carrying amounts and fair values of our other financial instruments were as follows: September 30, 2017 December 31, 2016 Carrying Amount Fair Value Carrying Amount Fair Value (in thousands) Assets: Investments in direct financing leases – net $ 364,997 $ 364,997 $ 601,938 $ 598,665 Mortgage notes receivable – net 666,606 681,274 639,343 644,961 Other investments – net 273,821 268,559 256,846 253,385 Total $ 1,305,424 $ 1,314,830 $ 1,498,127 $ 1,497,011 Liabilities: Revolving line of credit $ 365,000 $ 365,000 $ 190,000 $ 190,000 Tranche A-1 term loan — — 198,830 200,000 Tranche A-2 term loan — — 200,000 200,000 Tranche A-3 term loan — — 347,449 350,000 U.S. term loan 422,357 425,000 — — Sterling term loan 133,167 133,980 — — Omega OP term loan (1) 99,390 100,000 100,000 100,000 2015 term loan 248,308 250,000 248,064 250,000 4.375% notes due 2023 – net 693,182 723,921 692,305 693,505 5.875% notes due 2024 – net — — 395,065 432,938 4.95% notes due 2024 – net 393,427 424,607 392,669 406,361 4.50% notes due 2025 – net 394,450 409,281 245,949 249,075 5.25% notes due 2026 – net 594,145 634,839 593,616 611,461 4.50% notes due 2027 – net 686,150 704,374 685,052 681,978 4.75% notes due 2028 – net 539,630 564,845 — — HUD debt – net (1) 53,419 52,778 54,365 52,510 Subordinated debt – net 20,403 23,946 20,490 23,944 Other 1,500 1,500 3,000 3,000 Total $ 4,644,528 $ 4,814,071 $ 4,366,854 $ 4,444,772 (1) These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP. Fair value estimates are subjective in nature and are dependent on a number of important assumptions, including estimates of future cash flows, risks, discount rates and relevant comparable market information associated with each financial instrument (see Note 2 – Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2016, as amended). The use of different market assumptions and estimation methodologies may have a material effect on the reported estimated fair value amounts. The following methods and assumptions were used in estimating fair value disclosures for financial instruments. · Direct financing leases: The fair value of the investments in direct financing leases are estimated using a discounted cash flow analysis, using interest rates being offered for similar leases to borrowers with similar credit ratings (Level 3). In addition, the Company may estimate the fair value of the investment based on the estimated fair value of the collateral using a market approach or an income approach which considers inputs such as, current and projected operating performance of the facilities, projected rent, prevailing capitalization rates and coverages and bed values (Level 3). · Mortgage notes receivable: The fair value of the mortgage notes receivables are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3). · Other investments: Other investments are primarily comprised of notes receivable. The fair values of notes receivable are estimated using a discounted cash flow analysis, using interest rates being offered for similar loans to borrowers with similar credit ratings (Level 3). · Revolving line of credit and term loans: The fair value of our borrowings under variable rate agreements are estimated using a present value technique based on expected cash flows discounted using the current market rates (Level 3). · Senior notes and subordinated debt: The fair value of our borrowings under fixed rate agreements are estimated using a present value technique based on inputs from trading activity provided by a third party (Level 2). · HUD debt: The fair value of our borrowings under HUD debt agreements are estimated using an expected present value technique based on quotes obtained by HUD debt brokers (Level 2).

LITIGATION

LITIGATION	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
LITIGATION	NOTE 15 – LITIGATION We are subject to various legal proceedings, claims and other actions arising out of the normal course of business. While any legal proceeding or claim has an element of uncertainty, management believes that the outcome of each lawsuit, claim or legal proceeding that is pending or threatened, or all of them combined, will not have a material adverse effect on our consolidated financial position or results of operations.

EARNINGS PER SHARE_UNIT

EARNINGS PER SHARE/UNIT	9 Months Ended
	Sep. 30, 2017
Net Income Available To Common Per Share
EARNINGS PER SHARE/UNIT	NOTE 16 – EARNINGS PER SHARE/UNIT The computation of basic earnings per share/unit (“EPS” or “EPU”) is computed by dividing net income available to common stockholders/Omega OP Unit holders by the weighted-average number of shares of common stock/Omega OP Units outstanding during the relevant period. Diluted EPS/EPU is computed using the treasury stock method, which is net income divided by the total weighted-average number of common outstanding shares/Omega OP Units plus the effect of dilutive common equivalent shares/units during the respective period. Dilutive common shares/Omega OP Units reflect the assumed issuance of additional common shares pursuant to certain of our share-based compensation plans, including stock options, restricted stock and performance restricted stock units and the assumed issuance of additional shares related to Omega OP Units held by outside investors. Dilutive Omega OP Units reflect the assumed issuance of additional Omega OP Units pursuant to certain of our share-based compensation plans, including stock options, restricted stock and performance restricted stock. The following tables set forth the computation of basic and diluted earnings per share/unit: Omega Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 (in thousands, except per share amounts) Numerator: Net (loss) income $ (137,515 ) $ 82,134 $ 39,754 $ 253,484 Less: net loss (income) attributable to noncontrolling interests 5,837 (3,585 ) (1,735 ) (11,328 ) Net (loss) income available to common stockholders $ (131,678 ) $ 78,549 $ 38,019 $ 242,156 Denominator: Denominator for basic earnings per share 197,890 194,123 197,445 190,444 Effect of dilutive securities: Common stock equivalents — 1,093 271 1,174 Noncontrolling interest – Omega OP Units 8,772 8,862 8,786 8,910 Denominator for diluted earnings per share 206,662 204,078 206,502 200,528 Earnings per share – basic: Net (loss) income available to common stockholders $ (0.67 ) $ 0.40 $ 0.19 $ 1.27 Earnings per share – diluted: Net (loss) income $ (0.67 ) $ 0.40 $ 0.19 $ 1.26 Omega OP Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 (in thousands, except per share amounts) Numerator: Net (loss) income $ (137,515 ) $ 82,134 $ 39,754 $ 253,484 Denominator: Denominator for basic earnings per unit 206,662 202,985 206,231 199,354 Effect of dilutive securities: Omega OP Unit equivalents — 1,093 271 1,174 Denominator for diluted earnings per unit 206,662 204,078 206,502 200,528 Earnings per unit – basic: Net (loss) income available to Omega OP Unit holders $ (0.67 ) $ 0.40 $ 0.19 $ 1.27 Earnings per unit – diluted: Net (loss) income $ (0.67 ) $ 0.40 $ 0.19 $ 1.26

SUPPLEMENTAL DISCLOSURE TO CONS

SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS	9 Months Ended
	Sep. 30, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS	NOTE 17 – SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS The following are supplemental disclosures to the consolidated statements of cash flows for the nine months ended September 30, 2017 and 2016: Nine Months Ended September 30, 2017 2016 Interest paid during the period, net of amounts capitalized $ 147,266 $ 116,169 Taxes paid during the period $ 3,124 $ 1,662 Non cash investing activities Non cash acquisition of real estate (See Note 2) $ (27,170 ) $ — Non cash acquisition of business — (60,079 ) Non cash surrender of mortgage — 25,000 Non cash investment in other investments (6,353 ) — Non cash proceeds from other investments (see Note 5) 30,187 5,500 Non cash settlement of direct financing lease (See Note 3) 18,989 — Total $ 15,653 $ (29,579 ) Non cash financing activities Purchase option buyout obligation $ — $ 29,579 Change in fair value of cash flow hedges (276 ) 12,094 Other unsecured long term borrowing — 3,000 Remeasurement of debt denominated in a foreign currency 5,920 — Total $ 5,644 $ 44,673

BASIS OF PRESENTATION AND SIG27

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for the interim periods reported herein are not necessarily indicative of results to be expected for the full year. These unaudited consolidated financial statements should be read in conjunction with the financial statements and the footnotes thereto included in our Form 10-K/A filed with the SEC on August 9, 2017. Omega’s consolidated financial statements include the accounts of (i) Omega, (ii) Omega OP, and (iii) all direct and indirect wholly owned subsidiaries of Omega. All intercompany transactions and balances have been eliminated in consolidation and our net earnings are reduced by the portion of net earnings attributable to noncontrolling interests. Omega OP’s consolidated financial statements include the accounts of (i) Omega OP, and (ii) all direct and indirect wholly owned subsidiaries of Omega OP. All intercompany transactions and balances have been eliminated in consolidation.
Real Estate Investment Impairment	Real Estate Investment Impairment Management evaluates our real estate investments for impairment indicators at each reporting period, including the evaluation of our assets’ useful lives. The judgment regarding the existence of impairment indicators is based on factors such as, but not limited to, market conditions, operator performance, legal structure, as well as our intent with respect to holding or disposing of the asset. If indicators of impairment are present, management evaluates the carrying value of the related real estate investments in relation to the future undiscounted cash flows of the underlying facilities. The estimated future undiscounted cash flows are generally based on the related lease which relates to one or more properties. In cases where the Company decides to separate one or more properties from the related lease in anticipation of a sale or transition of the property to another operator, the estimated undiscounted future cash flows specific to those properties are separated from the related lease at that time. Provisions for impairment losses related to long-lived assets are recognized when expected future undiscounted cash flows based on our intended use of the property are determined to be less than the carrying values of the assets. An adjustment is made to the net carrying value of the real estate investments for the excess of carrying value over fair value. The fair value of the real estate investment is determined based on current market conditions and consider matters such as rental rates and occupancies for comparable properties, recent sales data for comparable properties, and, where applicable, contracts or the results of negotiations with purchasers or prospective purchasers. Additionally, our evaluation of fair value may consider valuing the property as a nursing home as well as alternative uses. All impairments are taken as a period cost at that time, and depreciation is adjusted going forward to reflect the new value assigned to the asset. Management’s impairment evaluation process, and when applicable, impairment calculations involve estimation of the future cash flows from management’s intended use of the property. Changes in the facts and circumstances that drive management’s assumptions may result in an impairment of the Company’s assets in a future period that could be material to the Company’s results of operations. For the three months ended September 30, 2017 and 2016, we recognized impairment losses on real estate properties of $17.8 million and $17.3 million, respectively. For the nine months ended September 30, 2017 and 2016, we recognized impairment losses on real estate properties of $35.6 million and $58.7 million, respectively. For additional information see Note 2 – Properties and Investments.
Allowance for Losses on Mortgages, Other Investments and Direct Financing Leases	Allowance for Losses on Mortgages, Other Investments and Direct Financing Leases The allowances for losses on mortgage notes receivable, other investments and direct financing leases (collectively, our “loans”) are maintained at a level believed adequate to absorb potential losses. The determination of the allowances is based on a quarterly evaluation of these loans, including general economic conditions and estimated collectability of loan payments. We evaluate the collectability of our loans receivable based on a combination of factors, including, but not limited to, delinquency status, financial strength of the borrower and guarantors and the value of the underlying collateral. If such factors indicate that there is greater risk of loan charge-offs, additional allowances or placement on non-accrual status may be required. A loan is impaired when, based on current information and events, it is probable that we will be unable to collect all amounts due as scheduled according to the contractual terms of the loan agreements. Consistent with this definition, all loans on non-accrual status are deemed impaired. To the extent circumstances improve and the risk of collectability is diminished, we will return these loans to full accrual status. When management identifies potential loan impairment indicators, the loan is written down to the present value of the expected future cash flows. In cases where expected future cash flows are not readily determinable, the loan is written down to the fair value of the underlying collateral. We may base our valuation on a loan’s observable market price, if any, or the fair value of collateral, net of sales costs, if the repayment of the loan is expected to be provided solely by the sale of the collateral. We account for impaired loans and direct financing leases using (a) the cost-recovery method, and/or (b) the cash basis method. We generally utilize the cost-recovery method for impaired loans or direct financing leases for which impairment reserves were recorded. We utilize the cash basis method for impaired loans or direct financing leases for which no impairment reserves were recorded because the net present value of the discounted cash flows expected under the loan or direct financing lease and/or the underlying collateral supporting the loan or direct financing lease were equal to or exceeded the book value of the loans or direct financing leases. Under the cost-recovery method, we apply cash received against the outstanding loan balance or direct financing lease prior to recording interest income. Under the cash basis method, we apply cash received to principal or interest income based on the terms of the agreement. As of September 30, 2017 and December 31, 2016, we had $181.8 million and $8.7 million, respectively, of reserves on our loans. For additional information see Note 3 – Direct Financing Leases, Note 4 – Mortgage Notes Receivable and Note 5 – Other Investments.
Goodwill Impairment	Goodwill Impairment We assess goodwill for potential impairment during the fourth quarter of each fiscal year, or during the year if an event or other circumstance indicates that we may not be able to recover the carrying amount of the net assets of the reporting unit. In evaluating goodwill for impairment on an interim basis, we assess qualitative factors such as a current macroeconomic conditions, state of the equity and capital markets and our overall financial and operating performance
Noncontrolling Interests	Noncontrolling Interests Noncontrolling interests is the portion of equity not attributable to the respective reporting entity. We present the portion of any equity that we do not own in consolidated entities as noncontrolling interests and classify those interests as a component of total equity, separate from total stockholders’ equity, or owners’ equity on our Consolidated Balance Sheets. We include net (loss) income attributable to the noncontrolling interests in net income in our Consolidated Statements of Operations. As our ownership of a controlled subsidiary increases or decreases, any difference between the aggregate consideration paid to acquire the noncontrolling interests and our noncontrolling interest balance is recorded as a component of equity in additional paid-in capital, so long as we maintain a controlling ownership interest. The noncontrolling interest for Omega represents the outstanding Omega OP Units held by outside investors.
Foreign Operations	Foreign Operations The U.S. dollar is the functional currency for our consolidated subsidiaries operating in the U.S. The functional currency for our consolidated subsidiaries operating in the U.K. is the British Pound. For our consolidated subsidiaries whose functional currency is not the U.S. dollar, we translate their financial statements into the U.S. dollar. We translate assets and liabilities at the exchange rate in effect as of the financial statement date. Revenue and expense accounts are translated using an average exchange rate for the period. Gains and losses resulting from translation are included in Omega OP’s owners’ equity and Omega’s accumulated other comprehensive loss (“AOCL”), as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interests. We and certain of our consolidated subsidiaries may have intercompany and third-party debt that is not denominated in the entity’s functional currency. When the debt is remeasured against the functional currency of the entity, a gain or loss can result. The resulting adjustment is reflected in results of operations, unless it is intercompany debt that is deemed to be long-term in nature and then the adjustments are included in Omega OP’s owners’ equity and Omega’s AOCL.
Derivative Instruments	Derivative Instruments Cash flow hedges During our normal course of business, we may use certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at the inception of a qualifying cash flow hedging relationship, the underlying transaction or transactions, must be, and are expected to remain, probable of occurring in accordance with the Company’s related assertions. The Company recognizes all derivative instruments, including embedded derivatives required to be bifurcated, as assets or liabilities in the Consolidated Balance Sheets at their fair value which are determined using a market approach and Level 2 inputs. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria of hedge accounting are recognized in earnings. For derivatives designated as qualifying cash flow hedging relationships, the change in fair value of the effective portion of the derivatives is recognized in Omega OP’s owners’ equity and Omega’s AOCL as a separate component of equity and a proportionate amount of gain or loss is allocated to noncontrolling interest, whereas the change in fair value of the ineffective portion is recognized in earnings. We formally document all relationships between hedging instruments and hedged items, as well as our risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific forecasted transactions as well as recognized obligations or assets in the Consolidated Balance Sheets. We also assess and document, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying forecasted transaction will not occur, we discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the current fair value of the derivative. As a matter of policy, we do not use derivatives for trading or speculative purposes. At September 30, 2017 and December 31, 2016, we had $1.2 million and $1.5 million, respectively, of qualifying cash flow hedges recorded at fair value in accrued expenses and other liabilities on our Consolidated Balance Sheets. Net investment hedge We use the spot method to measure the effectiveness of our net investment hedge. Under this method, for each reporting period, the change in the carrying value of the hedging instrument due to remeasurement of the effective portion is reported in Omega OP’s owners’ equity and Omega’s AOCL in our Consolidated Balance Sheets and the remaining change in the carrying value of the ineffective portion, if any, is recognized in earnings. We evaluate the effectiveness of our net investment hedge on a quarterly basis. We did not record any ineffectiveness for fiscal 2017.
Accounts Receivable	Accounts Receivable Accounts receivable includes: contractual receivables, effective yield interest receivables, straight-line rent receivables and lease inducements, net of an estimated provision for losses related to uncollectible and disputed accounts. Contractual receivables relate to the amounts currently owed to us under the terms of our lease and loan agreements. Effective yield interest receivables relate to the difference between the interest income recognized on an effective yield basis over the term of the loan agreement and the interest currently due to us according to the contractual agreement. Straight-line rent receivables relate to the difference between the rental revenue recognized on a straight-line basis and the amounts currently due to us according to the contractual agreement. Lease inducements result from value provided by us to the lessee, at the inception or renewal of the lease, and are amortized as a reduction of rental revenue over the non-cancellable lease term. On a quarterly basis, we review our accounts receivable to determine their collectability. The determination of collectability of these assets requires significant judgment and is affected by several factors relating to the credit quality of our operators that we regularly monitor, including (i) payment history, (ii) the age of the contractual receivables, (iii) the current economic conditions and reimbursement environment, (iv) the ability of the tenant to perform under the terms of their lease and/or contractual loan agreements and (v) the value of the underlying collateral of the agreement. If we determine collectability of any of our contractual receivables is at risk, we estimate the potential uncollectible amounts and provide an allowance. In the case of a lease recognized on a straight-line basis, a mortgage recognized on an effective yield basis or the existence of lease inducements, we generally provide an allowance for straight-line, effective interest, and/or lease inducement accounts receivable when certain conditions or indicators of adverse collectability are present. If the accounts receivable balance is subsequently deemed uncollectible, the receivable and allowance for doubtful account balance are written off. At September 30, 2017, three of our operators were approximately 90 days or more past due on rent/interest payments to the Company. Two of these operators are considered top ten operators as determined based on total revenue. Of these three operators, rent/interest from two of these operators is being recognized on a cash basis as of September 30, 2017. A summary of our accounts receivable by type is as follows: September 30, December 31, 2017 2016 (in thousands) Contractual receivables $ 42,085 $ 13,376 Effective yield interest receivables 11,307 9,749 Straight-line rent receivables 218,292 208,874 Lease inducements 7,051 8,393 Allowance for contractual receivables (8,989 ) (357 ) Accounts receivable – net $ 269,746 $ 240,035 During the third quarter of 2017, the Company recorded a provision for uncollectible accounts of approximately $9.5 million related to contractual and straight-line rent receivables for one of our top ten operators. See Note 3 – Direct Financing Leases for additional information.
Related Party Transactions	Related Party Transactions The Company has a policy which generally requires related party transactions to be approved or ratified by the Audit Committee. On February 1, 2016, we acquired 10 SNFs from Laurel Healthcare Holdings, Inc. (“Laurel”) for approximately $169.0 million in cash and leased them to an unrelated existing operator. A former member of the Board of Directors of the Company, together with certain members of his immediate family, beneficially owned approximately 34% of the equity of Laurel prior to the transaction. Immediately following our acquisition, the unrelated existing operator acquired all of the outstanding equity interests of Laurel, including the interests previously held by the former director of the Company and his family.
Reclassification	Reclassification Certain prior quarter amounts have been reclassified to conform with the current quarter presentation.
Accounting Pronouncement Adopted in 2017	Accounting Pronouncement Adopted in 2017 In March 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-09, Compensation-Stock Compensation (Topic 718)
Recent Accounting Pronouncements - Pending Adoption	Recent Accounting Pronouncements - Pending Adoption In 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers Principal versus Agent Considerations (Reporting Revenue Gross versus Net), Identifying Performance Obligations and Licensing, Narrow-Scope Improvements and Practical Expedients. In February 2016, the FASB issued ASU 2016-02, Leases In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326 In August 2017 the FASB issued ASU 2017-12, Derivatives and Hedging: Targeted Improvements to Accounting for Hedging Activities

BASIS OF PRESENTATION AND SIG28

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Schedule of net accounts receivable	September 30, December 31, 2017 2016 (in thousands) Contractual receivables $ 42,085 $ 13,376 Effective yield interest receivables 11,307 9,749 Straight-line rent receivables 218,292 208,874 Lease inducements 7,051 8,393 Allowance for contractual receivables (8,989 ) (357 ) Accounts receivable – net $ 269,746 $ 240,035

PROPERTIES AND INVESTMENTS (Tab

PROPERTIES AND INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2017
Real Estate [Abstract]
Schedule of investment in leased real estate properties	September 30, December 31, 2017 2016 (in thousands) Buildings $ 6,249,790 $ 5,954,771 Land 818,014 759,295 Furniture, fixtures and equipment 471,495 454,760 Site improvements 225,455 206,206 Construction in progress 212,289 191,326 Total real estate investments 7,977,043 7,566,358 Less accumulated depreciation (1,432,154 ) (1,240,336 ) Real estate investments - net $ 6,544,889 $ 6,326,022
Schedule of significant acquisitions	Number of Country/ Total Land Building & Site Improvements Furniture Initial (2) Period SNF ALF State (in millions) (%) Q1 - 1 VA $ 7.6 $ 0.5 $ 6.8 $ 0.3 7.50 Q2 1 - NC 8.6 0.7 7.3 0.6 9.50 Q2 - 18 UK 124.2 (1) 34.1 85.1 5.0 8.50 Q3 - 1 TX 2.3 0.7 1.5 0.1 9.25 Q3 15 - IN 211.0 18.0 180.2 12.8 9.50 Q3 9 - TX 19.0 (3) 1.7 15.5 1.8 18.60 Total 25 20 $ 372.7 $ 55.7 $ 296.4 $ 20.6 (1) Omega recorded a non-cash deferred tax liability and acquisition costs of approximately $8.2 million and $1.2 million, respectively, in connection with this acquisition. (2) The cash yield is based on the purchase price. (3) In July 2017, we transitioned nine SNFs formerly subject to a direct financing lease to another operator. As a result of terminating the direct financing lease, we wrote down the facilities to our original cost basis and recorded an impairment on the direct financing lease of approximately $1.8 million. See Note 3 – Direct Financing Leases for additional information.

DIRECT FINANCING LEASES (Tables

DIRECT FINANCING LEASES (Tables)	9 Months Ended
	Sep. 30, 2017
DIRECT FINANCING LEASES - MINIMUM RENTS
Schedule of components of investment in direct financing leases	September 30, December 31, 2017 2016 (in thousands) Minimum lease payments receivable $ 3,716,562 $ 4,287,069 Less unearned income (3,179,625 ) (3,685,131 ) Investment in direct financing leases 536,937 601,938 Less allowance for loss on direct financing lease (171,940 ) — Investment in direct financing leases – net $ 364,997 $ 601,938 Properties subject to direct financing leases 42 58
Schedule of rents due under direct financing leases for remainder of 2017 and subsequent five years	2017 (1) 2018 (1) 2019 (1) 2020 (1) 2021 (1) 2022 (1) $ 11,245 $ 45,798 $ 46,920 $ 48,059 $ 49,136 $ 50,349 (1) Orianna represents approximately 94% of the contractual minimum rent payments due under our direct financing leases.

MORTGAGE NOTES RECEIVABLE (Tabl

MORTGAGE NOTES RECEIVABLE (Tables)	9 Months Ended
	Sep. 30, 2017
Mortgage Notes Receivable Investments [Abstract]
Schedule of outstanding principal amounts of mortgage notes receivable, net of allowances	September 30, December 31, 2017 2016 (in thousands) Mortgage note due 2024; interest at 9.98% $ 112,500 $ 112,500 Mortgage note due 2029; interest at 9.68% 411,119 412,140 Other mortgage notes outstanding (1) 147,734 118,637 Mortgage notes receivable, gross 671,353 643,277 Allowance for loss on mortgage notes receivable (4,747 ) (3,934 ) Total mortgages — net $ 666,606 $ 639,343 (1) Other mortgage notes outstanding have stated interest rates ranging from 8.35% to 14.0% and maturity dates through 2029.

OTHER INVESTMENTS (Tables)

OTHER INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2017
Receivables [Abstract]
Schedule of other investments	September 30, December 31, 2017 2016 (in thousands) Other investment note due 2019; interest at 10.99% $ 49,646 $ 49,458 Other investment note due 2020; interest at 14.43% 47,841 47,913 Other investment note due 2022, interest at 9.00% 31,987 31,987 Other investment note due 2030; interest at 6.66% 50,000 44,595 Other investment notes outstanding (1) 99,362 87,691 Other investments, gross 278,836 261,644 Allowance for loss on other investments (5,015 ) (4,798 ) Total other investments $ 273,821 $ 256,846 (1) Other investment notes have maturity dates through 2028 and interest rates ranging from 6.50% to 12.0%.

ASSETS HELD FOR SALE (Tables)

ASSETS HELD FOR SALE (Tables)	9 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment Assets Held-for-sale Disclosure [Abstract]
Schedule of properties held-for-sale	Properties Held For Sale Number of Net Book Value December 31, 2016 20 $ 52,868 Properties sold/other (1) (12 ) (30,023 ) Properties added (2) 1 400 March 31, 2017 9 $ 23,245 Properties sold/other (1) (2 ) (4,356 ) June 30, 2017 7 $ 18,889 Properties sold/other (1) (1 ) (3,075 ) Properties added (2) 2 1,510 September 30, 2017 (3) 8 $ 17,324 (1) In the first quarter of 2017, we sold nine SNFs and two ALFs for approximately $29.4 million in net proceeds recognizing a gain on sale of approximately $3.6 million. One SNF classified as an asset held for sale at December 31, 2016 was no longer considered held for sale during the first quarter of 2017 and was reclassified back to leased properties at approximately $5.1 million which represents the facility’s then carrying value adjusted for depreciation that was not recognized while classified as held for sale. In the second quarter of 2017, we sold one ALF and one SNF for approximately $5.0 million in net proceeds, generating a gain on sale of approximately $0.6 million. In the third quarter of 2017, we sold one SNF for approximately $3.1 million in net proceeds recognizing a gain of $0.3 million. (2) In the first quarter of 2017, we recorded a $3.5 million impairment to reduce one ALF’s net book value to its estimated fair value less costs to sell before it was reclassified to assets held for sale. In the third quarter of 2017, we recorded a $4.5 million impairment to reduce two SNFs to their estimated fair value less costs to sell before they were reclassified to assets held for sale. (3) We plan to sell the facilities classified as held for sale at September 30, 2017 within the next twelve months.

INTANGIBLES (Tables)

INTANGIBLES (Tables)	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangibles	September 30, December 31, 2017 2016 (in thousands) Assets: Goodwill $ 644,571 $ 643,474 Above market leases $ 22,426 $ 22,476 In-place leases 167 167 Accumulated amortization (16,791 ) (15,864 ) Net intangible assets $ 5,802 $ 6,779 Liabilities: Below market leases $ 164,443 $ 165,028 Accumulated amortization (80,747 ) (70,738 ) Net intangible liabilities $ 83,696 $ 94,290
Schedule of reconciliation of goodwill	(in thousands) Balance as of December 31, 2016 $ 643,474 Add: foreign currency translation 1,097 Balance as of September 30, 2017 $ 644,571

STOCKHOLDERS'_OWNERS' EQUITY (T

STOCKHOLDERS'/OWNERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Schedule of common stock dividends	Record Date Payment Date Dividend per Increase over January 31, 2017 February 15, 2017 $ 0.62 $ 0.01 May 1, 2017 May 15, 2017 0.63 0.01 August 1, 2017 August 15, 2017 0.64 0.01 October 31, 2017 November 15, 2017 0.65 0.01
Schedule of accumulated other comprehensive loss	As of and For the Three Months Ended September 30, As of and For the Nine Months Ended September 30, 2017 2016 2017 2016 (in thousands) Foreign Currency Translation: Beginning balance $ (40,340 ) $ (34,979 ) $ (54,948 ) $ (8,413 ) Translation gain (loss) 10,870 (6,623 ) 25,338 (33,167 ) Realized gain (loss) 95 (222 ) 235 (244 ) Ending balance (29,375 ) (41,824 ) (29,375 ) (41,824 ) Derivative Instruments: Cash flow hedges: Beginning balance (1,380 ) (13,792 ) (1,420 ) (718 ) Unrealized loss (gain) (332 ) 980 (1,682 ) (12,094 ) Realized gain (1) 490 - 1,880 - Ending balance (1,222 ) (12,812 ) (1,222 ) (12,812 ) Net investment hedge: Beginning balance (2,193 ) - - - Unrealized loss (3,750 ) - (5,943 ) - Ending balance (5,943 ) - (5,943 ) - Total accumulated other comprehensive loss for Omega OP (2) (36,540 ) (54,636 ) (36,540 ) (54,636 ) Add: portion included in noncontrolling interest 1,697 2,466 1,697 2,466 Total accumulated other comprehensive loss for Omega $ (34,843 ) $ (52,170 ) $ (34,843 ) $ (52,170 ) (1) Recorded in interest expense on the Consolidated Statements of Operations. (2) These amounts are included in owners’ equity.

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Schedule of stock-based compensation expense	Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 (in thousands) Stock-based compensation expense $ 3,872 $ 3,673 $ 11,350 $ 10,116
Schedule of unrecognized compensation cost associated with outstanding restricted stock and PRSU awards and LTIP Unit awards	Grant Shares/ Units Grant Date Total Compensation Cost (in millions) (1) Weighted Unrecognized Performance Vesting RSUs 3/31/15 RSU 2015 109,985 $ 40.57 $ 4.5 33 $ 0.4 N/A 12/31/2017 4/1/15 RSU 2015 40,464 40.74 1.6 33 0.2 N/A 12/31/2017 Assumed Aviv RSU 2015 7,799 35.08 0.3 33 - N/A 11/1/2017 3/17/16 RSU 2016 130,006 34.78 4.6 33 2.0 N/A 12/31/2018 1/1/2017 RSU 2017 140,416 31.26 4.3 36 3.3 N/A 12/31/2019 Restricted Stock Units Total 428,670 $ 35.68 $ 15.3 $ 5.9 TSR PRSUs and LTIP Units 2016 TSR 2014 135,634 $ 8.67 $ 1.2 48 $ 0.1 1/1/2014-12/31/2016 Quarterly in 2017 3/31/15 2017 LTIP Units 2015 137,249 14.66 2.0 45 0.7 1/1/2015-12/31/2017 Quarterly in 2018 4/1/2015 2017 LTIP Units 2015 53,387 14.81 0.8 45 0.2 1/1/2015-12/31/2017 Quarterly in 2018 3/17/2016 2018 LTIP Units 2016 370,152 13.21 4.9 45 2.9 1/1/2016-12/31/2018 Quarterly in 2019 1/1/2017 2019 LTIP Units 2017 399,726 12.61 5.0 48 4.1 1/1/2017-12/31/2019 Quarterly in 2020 TSR PRSUs & LTIP Total 1,096,148 $ 12.69 $ 13.9 $ 8.0 Relative TSR PRSUs 2016 Relative TSR 2014 135,634 $ 14.24 $ 1.9 48 $ 0.1 1/1/2014-12/31/2016 Quarterly in 2017 3/31/15 2017 Relative TSR 2015 137,249 22.50 3.1 45 1.0 1/1/2015-12/31/2017 Quarterly in 2018 4/1/2015 2017 Relative TSR 2015 53,387 22.92 1.2 45 0.4 1/1/2015-12/31/2017 Quarterly in 2018 3/17/2016 2018 Relative TSR 2016 305,563 16.44 5.1 45 2.9 1/1/2016-12/31/2018 Quarterly in 2019 1/1/2017 2019 Relative TSR 2017 285,338 18.04 5.1 48 4.2 1/1/2017-12/31/2019 Quarterly in 2020 Relative TSR PRSUs Total 917,171 $ 17.90 $ 16.4 $ 8.6 Grand Total 2,441,989 $ 18.68 $ 45.6 $ 22.5 (1) Total compensation costs are net of shares cancelled.

BORROWING ACTIVITIES AND ARRA37

BORROWING ACTIVITIES AND ARRANGEMENTS (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Schedule of borrowings	Annual Interest September 30, September 30, December 31, Maturity 2017 2017 2016 (in thousands) Secured borrowings: HUD mortgages assumed December 2011 (1) 2044 3.06 % $ 53,992 $ 54,954 Deferred financing costs – net (573 ) (589 ) Total secured borrowings – net (2) 53,419 54,365 Unsecured borrowings: Revolving line of credit 2021 2.49 % 365,000 190,000 Tranche A-1 term loan - - — 200,000 Tranche A-2 term loan - - — 200,000 Tranche A-3 term loan - - — 350,000 U.S. term loan 2022 2.69 % 425,000 — Sterling term loan 2022 1.70 % 133,980 — Omega OP term loan (2) 2022 2.69 % 100,000 100,000 2015 term loan 2022 3.80 % 250,000 250,000 Discounts and deferred financing costs – net (3) (5,759 ) (5,657 ) Total term loans – net 903,221 1,094,343 2023 notes 2023 4.375 % 700,000 700,000 2024 notes 2024 5.875 % — 400,000 2024 notes 2024 4.95 % 400,000 400,000 2025 notes 2025 4.50 % 400,000 250,000 2026 notes 2026 5.25 % 600,000 600,000 2027 notes 2027 4.50 % 700,000 700,000 2028 notes 2028 4.75 % 550,000 — Other 2018 - 1,500 3,000 Subordinated debt 2021 9.00 % 20,000 20,000 Discount - net (21,709 ) (17,151 ) Deferred financing costs – net (26,903 ) (27,703 ) Total unsecured borrowings – net 3,322,888 3,028,146 Total secured and unsecured borrowings – net $ 4,644,528 $ 4,366,854 (1) Reflects the weighted average annual contractual interest rate on the mortgages at September 30, 2017 excluding a third-party administration fee of approximately 0.5% annually. Secured by real estate assets with a net carrying value of $62.9 million as of September 30, 2017. (2) These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP. (3) This amount includes $0.6 million of net deferred financing costs related to the Omega OP term loan as of September 30, 2017.

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of carrying amounts and fair values of financial instruments	September 30, 2017 December 31, 2016 Carrying Amount Fair Value Carrying Amount Fair Value (in thousands) Assets: Investments in direct financing leases – net $ 364,997 $ 364,997 $ 601,938 $ 598,665 Mortgage notes receivable – net 666,606 681,274 639,343 644,961 Other investments – net 273,821 268,559 256,846 253,385 Total $ 1,305,424 $ 1,314,830 $ 1,498,127 $ 1,497,011 Liabilities: Revolving line of credit $ 365,000 $ 365,000 $ 190,000 $ 190,000 Tranche A-1 term loan — — 198,830 200,000 Tranche A-2 term loan — — 200,000 200,000 Tranche A-3 term loan — — 347,449 350,000 U.S. term loan 422,357 425,000 — — Sterling term loan 133,167 133,980 — — Omega OP term loan (1) 99,390 100,000 100,000 100,000 2015 term loan 248,308 250,000 248,064 250,000 4.375% notes due 2023 – net 693,182 723,921 692,305 693,505 5.875% notes due 2024 – net — — 395,065 432,938 4.95% notes due 2024 – net 393,427 424,607 392,669 406,361 4.50% notes due 2025 – net 394,450 409,281 245,949 249,075 5.25% notes due 2026 – net 594,145 634,839 593,616 611,461 4.50% notes due 2027 – net 686,150 704,374 685,052 681,978 4.75% notes due 2028 – net 539,630 564,845 — — HUD debt – net (1) 53,419 52,778 54,365 52,510 Subordinated debt – net 20,403 23,946 20,490 23,944 Other 1,500 1,500 3,000 3,000 Total $ 4,644,528 $ 4,814,071 $ 4,366,854 $ 4,444,772 (1) These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

EARNINGS PER SHARE_UNIT (Tables

EARNINGS PER SHARE/UNIT (Tables)	9 Months Ended
	Sep. 30, 2017
Net Income Available To Common Per Share
Schedule of computation of basic and diluted earnings per share	Omega Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 (in thousands, except per share amounts) Numerator: Net (loss) income $ (137,515 ) $ 82,134 $ 39,754 $ 253,484 Less: net loss (income) attributable to noncontrolling interests 5,837 (3,585 ) (1,735 ) (11,328 ) Net (loss) income available to common stockholders $ (131,678 ) $ 78,549 $ 38,019 $ 242,156 Denominator: Denominator for basic earnings per share 197,890 194,123 197,445 190,444 Effect of dilutive securities: Common stock equivalents — 1,093 271 1,174 Noncontrolling interest – Omega OP Units 8,772 8,862 8,786 8,910 Denominator for diluted earnings per share 206,662 204,078 206,502 200,528 Earnings per share – basic: Net (loss) income available to common stockholders $ (0.67 ) $ 0.40 $ 0.19 $ 1.27 Earnings per share – diluted: Net (loss) income $ (0.67 ) $ 0.40 $ 0.19 $ 1.26 Omega OP Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 (in thousands, except per share amounts) Numerator: Net (loss) income $ (137,515 ) $ 82,134 $ 39,754 $ 253,484 Denominator: Denominator for basic earnings per unit 206,662 202,985 206,231 199,354 Effect of dilutive securities: Omega OP Unit equivalents — 1,093 271 1,174 Denominator for diluted earnings per unit 206,662 204,078 206,502 200,528 Earnings per unit – basic: Net (loss) income available to Omega OP Unit holders $ (0.67 ) $ 0.40 $ 0.19 $ 1.27 Earnings per unit – diluted: Net (loss) income $ (0.67 ) $ 0.40 $ 0.19 $ 1.26

SUPPLEMENTAL DISCLOSURE TO CO40

SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS (Tables)	9 Months Ended
	Sep. 30, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Schedule of consolidated statements of cash flows	Nine Months Ended September 30, 2017 2016 Interest paid during the period, net of amounts capitalized $ 147,266 $ 116,169 Taxes paid during the period $ 3,124 $ 1,662 Non cash investing activities Non cash acquisition of real estate (See Note 2) $ (27,170 ) $ — Non cash acquisition of business — (60,079 ) Non cash surrender of mortgage — 25,000 Non cash investment in other investments (6,353 ) — Non cash proceeds from other investments (see Note 5) 30,187 5,500 Non cash settlement of direct financing lease (See Note 3) 18,989 — Total $ 15,653 $ (29,579 ) Non cash financing activities Purchase option buyout obligation $ — $ 29,579 Change in fair value of cash flow hedges (276 ) 12,094 Other unsecured long term borrowing — 3,000 Remeasurement of debt denominated in a foreign currency 5,920 — Total $ 5,644 $ 44,673

BASIS OF PRESENTATION AND SIG41

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Contractual receivables	$ 42,085	$ 13,376
Effective yield interest receivables	11,307	9,749
Straight-line rent receivables	218,292	208,874
Lease inducements	7,051	8,393
Allowance for contractual receivables	(8,989)	(357)
Accounts receivable - net	$ 269,746	$ 240,035

BASIS OF PRESENTATION AND SIG42

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Detail)	9 Months Ended
	Sep. 30, 2017Segment
Accounting Policies [Abstract]
Number of reportable segment	1

BASIS OF PRESENTATION AND SIG43

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Detail 1) $ in Thousands	Feb. 01, 2016USD ($)Facility	Sep. 30, 2017USD ($)Healthcare_facility	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)Healthcare_facilityOperator	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Basis Of Presentation And Significant Accounting Policies [Line Items]
Impairment losses recognized		$ 17,837	$ 17,275	$ 35,610	$ 58,726
Loan loss reserves		$ 181,800		$ 181,800		$ 8,700
Number of leased real estate properties | Healthcare_facility		1,012		1,012
Number of operators 90 days past due | Operator				3
Number of operators being recognized on a cash basis | Operator				2
Provision of contractual and straight-line rent receivables		$ 9,500		$ 9,500
SNF's
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of leased real estate properties | Healthcare_facility		772		772
Cash flow hedges
Basis Of Presentation And Significant Accounting Policies [Line Items]
Cash flow hedges recorded at fair value in accrued expenses and other liabilities		$ 1,200		$ 1,200		$ 1,500
Omega OP Units
Basis Of Presentation And Significant Accounting Policies [Line Items]
Percentage of limited partnership interests owned		96.00%		96.00%
Other Investors | Omega OP Units
Basis Of Presentation And Significant Accounting Policies [Line Items]
Percentage of limited partnership interests owned		4.00%		4.00%
Laurel | SNF's
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of leased real estate properties | Facility	10
Purchase price of buildings acquired paid in cash	$ 169,000
Percentage of ownership interest	34.00%

PROPERTIES AND INVESTMENTS - In

PROPERTIES AND INVESTMENTS - Investment in leased real estate properties (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Total real estate investments	$ 7,977,043	$ 7,566,358
Less accumulated depreciation	(1,432,154)	(1,240,336)
Real estate investments - net	6,544,889	6,326,022
Buildings
Property, Plant and Equipment [Line Items]
Total real estate investments	6,249,790	5,954,771
Land
Property, Plant and Equipment [Line Items]
Total real estate investments	818,014	759,295
Furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Total real estate investments	471,495	454,760
Site improvements
Property, Plant and Equipment [Line Items]
Total real estate investments	225,455	206,206
Construction in progress
Property, Plant and Equipment [Line Items]
Total real estate investments	$ 212,289	$ 191,326

PROPERTIES AND INVESTMENTS - Si

PROPERTIES AND INVESTMENTS - Significant acquisitions that occurred in 2017 (Detail 1) $ in Millions	9 Months Ended
	Sep. 30, 2017USD ($)FacilityHealthcare_facility
Real Estate Properties [Line Items]
Number of Facilities | Healthcare_facility	1,012
SNF's
Real Estate Properties [Line Items]
Number of Facilities | Healthcare_facility	772
ALFs
Real Estate Properties [Line Items]
Number of Facilities | Healthcare_facility	120
2017 acquisitions and other
Real Estate Properties [Line Items]
Total Investment	$ 372.7
2017 acquisitions and other | SNF's
Real Estate Properties [Line Items]
Number of Facilities | Facility	25
2017 acquisitions and other | ALFs
Real Estate Properties [Line Items]
Number of Facilities | Facility	20
2017 acquisitions and other | Land
Real Estate Properties [Line Items]
Total Investment	$ 55.7
2017 acquisitions and other | Building & Site Improvements
Real Estate Properties [Line Items]
Total Investment	296.4
2017 acquisitions and other | Furniture & Fixtures
Real Estate Properties [Line Items]
Total Investment	20.6
2017 acquisitions and other | Q1 | VA
Real Estate Properties [Line Items]
Total Investment	$ 7.6
Initial Annual Cash Yield (%)	7.50%	[1]
2017 acquisitions and other | Q1 | VA | ALFs
Real Estate Properties [Line Items]
Number of Facilities | Facility	1
2017 acquisitions and other | Q1 | VA | Land
Real Estate Properties [Line Items]
Total Investment	$ 0.5
2017 acquisitions and other | Q1 | VA | Building & Site Improvements
Real Estate Properties [Line Items]
Total Investment	6.8
2017 acquisitions and other | Q1 | VA | Furniture & Fixtures
Real Estate Properties [Line Items]
Total Investment	0.3
2017 acquisitions and other | Q2 | NC
Real Estate Properties [Line Items]
Total Investment	$ 8.6
Initial Annual Cash Yield (%)	9.50%	[1]
2017 acquisitions and other | Q2 | NC | SNF's
Real Estate Properties [Line Items]
Number of Facilities | Facility	1
2017 acquisitions and other | Q2 | NC | Land
Real Estate Properties [Line Items]
Total Investment	$ 0.7
2017 acquisitions and other | Q2 | NC | Building & Site Improvements
Real Estate Properties [Line Items]
Total Investment	7.3
2017 acquisitions and other | Q2 | NC | Furniture & Fixtures
Real Estate Properties [Line Items]
Total Investment	0.6
2017 acquisitions and other | Q2 | UK
Real Estate Properties [Line Items]
Total Investment	$ 124.2	[2]
Initial Annual Cash Yield (%)	8.50%	[1]
2017 acquisitions and other | Q2 | UK | ALFs
Real Estate Properties [Line Items]
Number of Facilities | Facility	18
2017 acquisitions and other | Q2 | UK | Land
Real Estate Properties [Line Items]
Total Investment	$ 34.1
2017 acquisitions and other | Q2 | UK | Building & Site Improvements
Real Estate Properties [Line Items]
Total Investment	85.1
2017 acquisitions and other | Q2 | UK | Furniture & Fixtures
Real Estate Properties [Line Items]
Total Investment	5
2017 acquisitions and other | Q3 | TX
Real Estate Properties [Line Items]
Total Investment	$ 2.3
Initial Annual Cash Yield (%)	9.25%	[1]
2017 acquisitions and other | Q3 | TX | ALFs
Real Estate Properties [Line Items]
Number of Facilities | Facility	1
2017 acquisitions and other | Q3 | TX | Land
Real Estate Properties [Line Items]
Total Investment	$ 0.7
2017 acquisitions and other | Q3 | TX | Building & Site Improvements
Real Estate Properties [Line Items]
Total Investment	1.5
2017 acquisitions and other | Q3 | TX | Furniture & Fixtures
Real Estate Properties [Line Items]
Total Investment	0.1
2017 acquisitions and other | Q3 | IN
Real Estate Properties [Line Items]
Total Investment	$ 211
Initial Annual Cash Yield (%)	9.50%	[1]
2017 acquisitions and other | Q3 | IN | SNF's
Real Estate Properties [Line Items]
Number of Facilities | Facility	15
2017 acquisitions and other | Q3 | IN | Land
Real Estate Properties [Line Items]
Total Investment	$ 18
2017 acquisitions and other | Q3 | IN | Building & Site Improvements
Real Estate Properties [Line Items]
Total Investment	180.2
2017 acquisitions and other | Q3 | IN | Furniture & Fixtures
Real Estate Properties [Line Items]
Total Investment	12.8
2017 acquisitions and other | Q3 | TX
Real Estate Properties [Line Items]
Total Investment	$ 19	[3]
Initial Annual Cash Yield (%)	18.60%	[1]
2017 acquisitions and other | Q3 | TX | SNF's
Real Estate Properties [Line Items]
Number of Facilities | Facility	9
2017 acquisitions and other | Q3 | TX | Land
Real Estate Properties [Line Items]
Total Investment	$ 1.7
2017 acquisitions and other | Q3 | TX | Building & Site Improvements
Real Estate Properties [Line Items]
Total Investment	15.5
2017 acquisitions and other | Q3 | TX | Furniture & Fixtures
Real Estate Properties [Line Items]
Total Investment	$ 1.8
[1]	The cash yield is based on the purchase price.
[2]	Omega recorded a non-cash deferred tax liability and acquisition costs of approximately $8.2 million and $1.2 million, respectively, in connection with this acquisition.
[3]	In July 2017, we transitioned nine SNFs formerly subject to a direct financing lease to another operator. As a result of terminating the direct financing lease, we wrote down the facilities to our original cost basis and recorded an impairment on the direct financing lease of approximately $1.8 million. See Note 3 - Direct Financing Leases for additional information.

PROPERTIES AND INVESTMENTS (Par

PROPERTIES AND INVESTMENTS (Parentheticals) (Detail 1) $ in Millions	1 Months Ended
	Jul. 31, 2017USD ($)Facility	Sep. 30, 2017USD ($)FacilityHealthcare_facility
Real Estate Properties [Line Items]
Number of real estate properties | Healthcare_facility		1,012
SNF's
Real Estate Properties [Line Items]
Number of real estate properties | Healthcare_facility		772
Facility Transition
Real Estate Properties [Line Items]
Recorded an impairment on direct financing lease	$ 1.8
2017 acquisitions and other | SNF's
Real Estate Properties [Line Items]
Number of real estate properties | Facility		25
2017 acquisitions and other | Facility Transition | SNF's
Real Estate Properties [Line Items]
Number of real estate properties | Facility	9
2017 acquisitions and other | Q2 | UK
Real Estate Properties [Line Items]
Deferred tax liability		$ 8.2
Acquisitions costs		$ 1.2

PROPERTIES AND INVESTMENTS - Le

PROPERTIES AND INVESTMENTS - Leased Property (Narrative) (Detail) $ in Millions	3 Months Ended	9 Months Ended
	Jun. 30, 2017USD ($)Parcel	Sep. 30, 2017FacilityHealthcare_facility
Real Estate Properties [Line Items]
Number of real estate properties		1,012
Property available for operating lease | Minimum
Real Estate Properties [Line Items]
Lease term		5 years
Increase in the specific annual percentage over the prior year's rent		2.00%
Property available for operating lease | Maximum
Real Estate Properties [Line Items]
Lease term		15 years
Increase in the specific annual percentage over the prior year's rent		3.00%
SNF's
Real Estate Properties [Line Items]
Number of real estate properties		772
ALFs
Real Estate Properties [Line Items]
Number of real estate properties		120
Specialty facilities
Real Estate Properties [Line Items]
Number of real estate properties		16
Medical office building
Real Estate Properties [Line Items]
Number of real estate properties		1
2017 acquisitions and other | SNF's
Real Estate Properties [Line Items]
Number of real estate properties | Facility		25
2017 acquisitions and other | ALFs
Real Estate Properties [Line Items]
Number of real estate properties | Facility		20
2017 acquisitions and other | Land
Real Estate Properties [Line Items]
Number of properties acquired | Parcel	2
Cash payment to acquire facilities | $	$ 5.5

PROPERTIES AND INVESTMENTS - As

PROPERTIES AND INVESTMENTS - Assets Sold or Held for Sale (Narrative) (Detail 1) $ in Millions	3 Months Ended
	Sep. 30, 2017USD ($)FacilityOperator	Jun. 30, 2017USD ($)Facility	Mar. 31, 2017USD ($)Facility
Real Estate [Abstract]
Number of facilities sold	2	3	15
Total cash proceeds | $	$ 5.7	$ 18.3	$ 45.8
Amount of gain (loss) from sale of facilities | $	$ 0.7	$ (0.6)	$ 7.4
Number of previously classified as held for sale	1	2	11
Provision for impairment on real estate properties | $	$ 15.3	$ 10.1	$ 7.6
Number of facilities with impairment charges	5	6	3
Number of facilities with impairment charges reclassified as held for sale			1
Number of subsequently reclassified as held for sale	2
Wrote off associated with the termination project | $	$ 2.5
Number of operator | Operator	1

DIRECT FINANCING LEASES (Detail

DIRECT FINANCING LEASES (Detail) $ in Thousands	Sep. 30, 2017USD ($)Property	Dec. 31, 2016USD ($)Property
DIRECT FINANCING LEASES - MINIMUM RENTS
Minimum lease payments receivable	$ 3,716,562	$ 4,287,069
Less unearned income	(3,179,625)	(3,685,131)
Investment in direct financing leases	536,937	601,938
Less allowance for loss on direct financing lease	(171,940)	0
Investment in direct financing leases - net	$ 364,997	$ 601,938
Properties subject to direct financing leases | Property	42	58

DIRECT FINANCING LEASES (Deta50

DIRECT FINANCING LEASES (Detail 1) $ in Thousands	Sep. 30, 2017USD ($)	[1]
DIRECT FINANCING LEASES - MINIMUM RENTS
2,017	$ 11,245
2,018	45,798
2,019	46,920
2,020	48,059
2,021	49,136
2,022	$ 50,349
[1]	Orianna represents approximately 94% of the contractual minimum rent payments due under our direct financing leases.

DIRECT FINANCING LEASES (Parent

DIRECT FINANCING LEASES (Parentheticals) (Detail 1)	9 Months Ended
	Sep. 30, 2017
DIRECT FINANCING LEASES - MINIMUM RENTS
Percentage of contractual minimum rent payments under direct financing leases	94.00%

DIRECT FINANCING LEASES (Narrat

DIRECT FINANCING LEASES (Narrative) (Detail) $ in Thousands	1 Months Ended		3 Months Ended				9 Months Ended
	Jul. 31, 2017USD ($)Facility	Nov. 27, 2013USD ($)FacilityLease	Sep. 30, 2017USD ($)FacilityHealthcare_facilityState	Jun. 30, 2017USD ($)Facility	Mar. 31, 2017USD ($)FacilityParty	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)FacilityHealthcare_facilityState	Sep. 30, 2016USD ($)
Capital Leased Assets [Line Items]
Number of facilities owned | Healthcare_facility			1,012				1,012
Number of states | State			42				42
Impairment on real estate properties			$ 17,837			$ 17,275	$ 35,610	$ 58,726
Income from direct financing leases			$ 614			$ 15,611	$ 31,722	$ 46,574
Northwest | Direct financing leases | Sales Agreement
Capital Leased Assets [Line Items]
Number of unrelated third parties | Party					2
Carrying amount of facility					$ 36,400
Number of facilities to be sold | Facility					7
Number of facilities sold | Facility			2	5			2
Proceeds from sale of facility			$ 5,800	$ 27,300	$ 34,000
Impairment on real estate properties				$ 900	$ 2,400
Orianna
Capital Leased Assets [Line Items]
Purchase price of beds acquired paid in cash		$ 529,000
Number of lease | Lease		4
Master lease term		50 years
Interest on lease per annum		10.60%
Number of additional owned as an operating lease | Facility			4				4
Impairment on real estate properties			$ 194,700				$ 198,000
Allowance for loss under direct financing leases			$ 171,900
Number of remaining facilities | Facility			39
Recorded investment in direct financing leases			$ 337,700
Recorded investment in operating lease			38,900				38,900
Allowance for contractual receivables			$ 1,900				$ 1,900
Orianna | Southeast
Capital Leased Assets [Line Items]
Number of states | State			7				7
Impairment on real estate properties	$ 20,800
Outstanding receivable reduction	19,300
Number of remaining facilities | Facility			38
Orianna | Indiana
Capital Leased Assets [Line Items]
Number of remaining facilities | Facility			1
SNF's | Texas
Capital Leased Assets [Line Items]
Impairment on real estate properties	$ 1,800
Number of facilities transitioned | Facility	9
Written down value of direct financing lease assets to original cost	$ 19,000
SNF's | Orianna | Direct financing leases
Capital Leased Assets [Line Items]
Number of facilities owned | Facility		55
ALFs | Orianna | Direct financing leases
Capital Leased Assets [Line Items]
Number of facilities owned | Facility		1

MORTGAGE NOTES RECEIVABLE (Deta

MORTGAGE NOTES RECEIVABLE (Details) - USD ($) $ in Thousands		9 Months Ended	12 Months Ended
		Sep. 30, 2017	Dec. 31, 2016
Mortgage Loans on Real Estate [Line Items]
Mortgage notes receivable, gross		$ 671,353	$ 643,277
Allowance for loss on mortgage notes receivable		(4,747)	(3,934)
Total mortgages - net		666,606	639,343
Mortgage note due 2024; interest at 9.98%
Mortgage Loans on Real Estate [Line Items]
Mortgage notes receivable, gross		$ 112,500	$ 112,500
Mortgage loans on real estate, interest rate		9.98%	9.98%
Mortgage note due 2029; interest at 9.68%
Mortgage Loans on Real Estate [Line Items]
Mortgage notes receivable, gross		$ 411,119	$ 412,140
Mortgage loans on real estate, interest rate		9.68%	9.68%
Other mortgage notes outstanding
Mortgage Loans on Real Estate [Line Items]
Mortgage notes receivable, gross	[1]	$ 147,734	$ 118,637
[1]	Other mortgage notes outstanding have stated interest rates ranging from 8.35% to 14.0% and maturity dates through 2029.

MORTGAGE NOTES RECEIVABLE (Pare

MORTGAGE NOTES RECEIVABLE (Parentheticals) (Details) - Other mortgage notes outstanding	9 Months Ended
	Sep. 30, 2017
Minimum
Mortgage Loans on Real Estate [Line Items]
Mortgage loans on real estate, interest rate	8.35%
Maximum
Mortgage Loans on Real Estate [Line Items]
Mortgage loans on real estate, interest rate	14.00%
Maturity year	2,029

MORTGAGE NOTES RECEIVABLE (Narr

MORTGAGE NOTES RECEIVABLE (Narrative) (Detail)	9 Months Ended
	Sep. 30, 2017FacilityStateEntity
Mortgage Loans on Real Estate [Line Items]
Number of states | State	42
Mortgage loans
Mortgage Loans on Real Estate [Line Items]
Number of fixed rate mortgages | Facility	29
Number of long term care facilities | Facility	52
Number of states | State	10
Number of independent healthcare operating companies | Entity	7

OTHER INVESTMENTS (Details)

OTHER INVESTMENTS (Details) - USD ($) $ in Thousands		Sep. 30, 2017	Dec. 31, 2016
Schedule of Investments [Line Items]
Other investments, gross		$ 278,836	$ 261,644
Allowance for loss on other investments		(5,015)	(4,798)
Total other investments		273,821	256,846
Other investment note due 2019; interest at 10.99%
Schedule of Investments [Line Items]
Other investments, gross		$ 49,646	$ 49,458
Interest rate		10.99%	10.99%
Other investment note due 2020; interest at 14.43%
Schedule of Investments [Line Items]
Other investments, gross		$ 47,841	$ 47,913
Interest rate		14.43%	14.43%
Other investment note due 2022, interest at 9.00%
Schedule of Investments [Line Items]
Other investments, gross		$ 31,987	$ 31,987
Interest rate		9.00%	9.00%
Other investment note due 2030; interest at 6.66%
Schedule of Investments [Line Items]
Other investments, gross		$ 50,000	$ 44,595
Interest rate		6.66%	6.66%
Other investment notes outstanding
Schedule of Investments [Line Items]
Other investments, gross	[1]	$ 99,362	$ 87,691
[1]	Other investment notes have maturity dates through 2028 and interest rates ranging from 6.50% to 12.0%.

OTHER INVESTMENTS (Parenthetica

OTHER INVESTMENTS (Parentheticals) (Details) - Other investment notes outstanding	9 Months Ended
	Sep. 30, 2017
Minimum
Schedule of Investments [Line Items]
Interest rate	6.50%
Maximum
Schedule of Investments [Line Items]
Interest rate	12.00%
Maturity year	2,028

OTHER INVESTMENTS (Narrative) (

OTHER INVESTMENTS (Narrative) (Detail) - USD ($) $ in Thousands	1 Months Ended
	Aug. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Schedule of Investments [Line Items]
Total Investments		$ 7,905,370	$ 7,925,793
Other Investment notes paid off
Schedule of Investments [Line Items]
Fair value of terminated purchase option buyout obligation	$ 30,700
Weighted average interest rate of terminated purchase option buyout obligation	10.50%
Total Investments	$ 30,200

INVESTMENT IN UNCONSOLIDATED 59

INVESTMENT IN UNCONSOLIDATED JOINT VENTURE (Details) $ in Thousands	Nov. 01, 2016USD ($)Facility	Sep. 30, 2017USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2016USD ($)
Schedule of Equity Method Investments [Line Items]
Investment in unconsolidated joint venture		$ 37,733	$ 37,733	$ 48,776
Assets management fees recognized		$ 500	$ 1,500
Second Spring Healthcare Investments
Schedule of Equity Method Investments [Line Items]
Investment in unconsolidated joint venture	$ 50,000
Percentage of ownership interest	15.00%
Second Spring Healthcare Investments | Affiliates of Lindsey Goldberg LLC
Schedule of Equity Method Investments [Line Items]
Percentage of ownership interest	85.00%
Second Spring Healthcare Investments | Welltower Inc | SNF's
Schedule of Equity Method Investments [Line Items]
Number of properties acquired | Facility	64
Payments to acquire facilities	$ 1,100,000

ASSETS HELD FOR SALE (Details)

ASSETS HELD FOR SALE (Details) $ in Thousands		3 Months Ended
		Sep. 30, 2017USD ($)Property		Jun. 30, 2017USD ($)Property	Mar. 31, 2017USD ($)Property
Number Of Properties
Beginning Balance | Property		7		9	20
Properties sold/other | Property	[1]	(1)		(2)	(12)
Properties added | Property	[2]	2			1
Ending balance | Property		8	[3]	7	9
Net Book Value
Beginning Balance | $		$ 18,889		$ 23,245	$ 52,868
Properties sold/other | $	[1]	(3,075)		(4,356)	(30,023)
Properties added | $	[2]	1,510			400
Ending balance | $		$ 17,324	[3]	$ 18,889	$ 23,245
[1]	In the first quarter of 2017, we sold nine SNFs and two ALFs for approximately $29.4 million in net proceeds recognizing a gain on sale of approximately $3.6 million. One SNF classified as an asset held for sale at December 31, 2016 was no longer considered held for sale during the first quarter of 2017 and was reclassified back to leased properties at approximately $5.1 million which represents the facility's then carrying value adjusted for depreciation that was not recognized while classified as held for sale. In the second quarter of 2017, we sold one ALF and one SNF for approximately $5.0 million in net proceeds, generating a gain on sale of approximately $0.6 million. In the third quarter of 2017, we sold one SNF for approximately $3.1 million in net proceeds recognizing a gain of $0.3 million.
[2]	In the first quarter of 2017, we recorded a $3.5 million impairment to reduce one ALF's net book value to its estimated fair value less costs to sell before it was reclassified to assets held for sale. In the third quarter of 2017, we recorded a $4.5 million impairment to reduce two SNFs to their estimated fair value less costs to sell before they were reclassified to assets held for sale.
[3]	We plan to sell the facilities classified as held for sale at September 30, 2017 within the next twelve months.

ASSETS HELD FOR SALE (Parenthet

ASSETS HELD FOR SALE (Parentheticals) (Details) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2017USD ($)Facility	Mar. 31, 2017USD ($)FacilityProperty	Sep. 30, 2017USD ($)Facility
Real Estate Properties [Line Items]
Net proceeds from sale of facilities held for sale	$ 5	$ 29.4
Gain (loss) from sale of facilities	$ 0.6	$ 3.6
Number of facilities with impairment charges | Facility		1
SNF's
Real Estate Properties [Line Items]
Number of facilities held for sale sold | Facility	1	9	1
Net proceeds from sale of facilities held for sale			$ 3.1
Gain (loss) from sale of facilities			0.3
Number of property reclassified | Property		1
Impairment charges			$ 4.5
Number of facilities with impairment charges | Facility			2
Carrying value for property reclassified		$ 5.1
ALFs
Real Estate Properties [Line Items]
Number of facilities held for sale sold | Facility	1	2
Impairment charges		$ 3.5
Number of facilities with impairment charges | Facility		1

INTANGIBLES - Summary of our in

INTANGIBLES - Summary of our intangibles (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Assets:
Goodwill	$ 644,571	$ 643,474
Accumulated amortization	(16,791)	(15,864)
Net intangible assets	5,802	6,779
Liabilities:
Below market leases	164,443	165,028
Accumulated amortization	(80,747)	(70,738)
Net intangible liabilities	83,696	94,290
Above market leases
Assets:
Gross intangible assets	22,426	22,476
In-place leases
Assets:
Gross intangible assets	$ 167	$ 167

INTANGIBLES - Reconciliation of

INTANGIBLES - Reconciliation of goodwill (Details 1) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Goodwill [Roll Forward]
Balance	$ 643,474
Add: foreign currency translation	1,097
Balance	$ 644,571

INTANGIBLES (Narrative) (Detail

INTANGIBLES (Narrative) (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 2.9	$ 3	$ 9.1	$ 11
Remainder of 2017	2.8		2.8
2,018	10.5		10.5
2,019	9.4		9.4
2,020	9.2		9.2
2,021	$ 8.6		$ 8.6

INTANGIBLES (Narrative) (Deta65

INTANGIBLES (Narrative) (Detail 1)	9 Months Ended
	Sep. 30, 2017
Finite-Lived Intangible Assets [Line Items]
Below market leases, weighted average remaining amortization	9 years
Above market lease intangibles
Finite-Lived Intangible Assets [Line Items]
Weighted average remaining amortization	8 years

CONCENTRATION OF RISK (Narrativ

CONCENTRATION OF RISK (Narrative) (Detail) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2017USD ($)Healthcare_facilityStateOperator	Sep. 30, 2017USD ($)Healthcare_facilityStateOperator	Dec. 31, 2016USD ($)
Concentration Risk [Line Items]
Number of facilities owned	1,012	1,012
Number of states | State	42	42
Number of operators | Operator	77	77
Gross investment in facilities, net of impairments and before reserve for uncollectible loans | $	$ 9,000,000	$ 9,000,000
Percentage share of real estate investments related to long-term care facilities	99.00%	99.00%
Number of facilities held-for-sale/closed	10	10
Other investments | $	$ 273,821	$ 273,821	$ 256,846
Investment in unconsolidated joint venture | $	$ 37,733	$ 37,733	$ 48,776
Ohio
Concentration Risk [Line Items]
Concentration percent by state	9.00%	9.00%
Florida
Concentration Risk [Line Items]
Concentration percent by state	9.00%	9.00%
Texas
Concentration Risk [Line Items]
Concentration percent by state	8.00%	8.00%
SNF's
Concentration Risk [Line Items]
Number of facilities owned	772	772
Number of facilities under fixed rate mortgage loan	47	47
ALFs
Concentration Risk [Line Items]
Number of facilities owned	120	120
Number of facilities under fixed rate mortgage loan	4	4
Specialty facilities
Concentration Risk [Line Items]
Number of facilities owned	16	16
Medical office building
Concentration Risk [Line Items]
Number of facilities owned	1	1
Ciena Healthcare
Concentration Risk [Line Items]
Revenues from operations	11.00%	10.00%

STOCKHOLDERS'_OWNERS' EQUITY (D

STOCKHOLDERS'/OWNERS' EQUITY (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Dividend [Line Items]
Dividend per Common Share	$ 0.64	$ 0.60	$ 1.89	$ 1.75
Board of Directors | January 31, 2017
Dividend [Line Items]
Record Date			Jan. 31, 2017
Payment Date			Feb. 15, 2017
Dividend per Common Share			$ 0.62
Increase over Prior Quarter			$ 0.01
Dividends Payable, Nature			Quarterly
Board of Directors | May 1, 2017
Dividend [Line Items]
Record Date			May 1, 2017
Payment Date			May 15, 2017
Dividend per Common Share			$ 0.63
Increase over Prior Quarter			$ 0.01
Dividends Payable, Nature			Quarterly
Board of Directors | August 1, 2017
Dividend [Line Items]
Record Date			Aug. 1, 2017
Payment Date			Aug. 15, 2017
Dividend per Common Share			$ 0.64
Increase over Prior Quarter			$ 0.01
Dividends Payable, Nature			Quarterly
Board of Directors | October 31, 2017
Dividend [Line Items]
Record Date			Oct. 31, 2017
Payment Date			Nov. 15, 2017
Dividend per Common Share			$ 0.65
Increase over Prior Quarter			$ 0.01
Dividends Payable, Nature			Quarterly

STOCKHOLDERS'_OWNERS' EQUITY 68

STOCKHOLDERS'/OWNERS' EQUITY (Details 1) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Ending balance : Accumulated other comprehensive loss for Omega OP	[1]	$ (36,540)	$ (54,636)	$ (36,540)	$ (54,636)
Add: portion included in noncontrolling interest		1,697	2,466	1,697	2,466
Total accumulated other comprehensive loss for Omega		(34,843)	(52,170)	(34,843)	(52,170)	$ (53,827)
Foreign Currency Translation
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance : Accumulated other comprehensive loss for Omega OP		(40,340)	(34,979)	(54,948)	(8,413)
Translation gain (loss)		10,870	(6,623)	25,338	(33,167)
Realized gain (loss)		95	(222)	235	(244)
Ending balance : Accumulated other comprehensive loss for Omega OP		(29,375)	(41,824)	(29,375)	(41,824)
Cash flow hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance : Accumulated other comprehensive loss for Omega OP		(1,380)	(13,792)	(1,420)	(718)
Unrealized loss (gain)		(332)	980	(1,682)	(12,094)
Realized gain (loss)	[2]	490		1,880
Ending balance : Accumulated other comprehensive loss for Omega OP		(1,222)	$ (12,812)	(1,222)	$ (12,812)
Net investment hedge
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance : Accumulated other comprehensive loss for Omega OP		(2,193)
Unrealized loss (gain)		(3,750)		(5,943)
Ending balance : Accumulated other comprehensive loss for Omega OP		$ (5,943)		$ (5,943)
[1]	These amounts are included in owners' equity.
[2]	Recorded in interest expense on the Consolidated Statements of Operations.

STOCKHOLDERS'_OWNERS' EQUITY (N

STOCKHOLDERS'/OWNERS' EQUITY (Narrative) (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017
Equity Shelf Program
Issuance of common stock (in shares)		718
Gross proceeds from issuance of common stock		$ 22,196
500 Million Equity Shelf Program
Equity Shelf Program
Issuance of common stock, average price per share	$ 31.73	$ 30.92
Sales price, equity distribution agreement	$ 500,000	$ 500,000
Issuance of common stock (in shares)	500	700
Gross proceeds from issuance of common stock	$ 15,600	$ 22,200

STOCKHOLDERS'_OWNERS' EQUITY 70

STOCKHOLDERS'/OWNERS' EQUITY (Narrative) (Detail 1) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017
Dividend [Line Items]
Issuance of common stock (in shares)		718
Gross proceeds from issuance of common stock		$ 22,196
Dividend Reinvestment and Common Stock Purchase Plan
Dividend [Line Items]
Issuance of common stock, average price per share	$ 30.39	$ 31.49
Issuance of common stock (in shares)	300	1,000
Gross proceeds from issuance of common stock	$ 10,400	$ 30,100

TAXES (Narrative) (Detail)

TAXES (Narrative) (Detail) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2017USD ($)Subsidiary	Sep. 30, 2017USD ($)Subsidiary
Income Tax Disclosure [Abstract]
Percentage of minimum taxable income is distributed	90.00%	90.00%
Permitted ownership of a taxable REIT subsidiary ("TRS"), maximum percentage	100.00%	100.00%
Net operating loss carry-forward	$ 0.7	$ 0.7
Number of subsidiary created REITs as per qualification rules | Subsidiary	5	5
Number of subsidiary elected for treated as TRSs | Subsidiary	2	2
State and local income tax provision	$ 0.7	$ 2.2
Provision (benefit) for foreign income taxes	$ 0.3	$ 0.5

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Stock-based compensation expense	$ 3,872	$ 3,673	$ 11,350	$ 10,116

STOCK-BASED COMPENSATION (Det73

STOCK-BASED COMPENSATION (Details 1) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/Units | shares	2,441,989
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 18.68
Total Compensation Cost	$ 45.6	[1]
Unrecognized Compensation Cost	$ 22.5
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/Units | shares	428,670
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 35.68
Total Compensation Cost	$ 15.3	[1]
Unrecognized Compensation Cost	$ 5.9
RSUs | 3/31/15 RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	109,985
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 40.57
Total Compensation Cost	$ 4.5	[1]
Weighted Average Period of Expense Recognition	33 months
Unrecognized Compensation Cost	$ 0.4
Vesting Dates	12/31/2017
RSUs | 4/1/15 RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	40,464
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 40.74
Total Compensation Cost	$ 1.6	[1]
Weighted Average Period of Expense Recognition	33 months
Unrecognized Compensation Cost	$ 0.2
Vesting Dates	12/31/2017
RSUs | Assumed Aviv RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	7,799
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 35.08
Total Compensation Cost	$ 0.3	[1]
Weighted Average Period of Expense Recognition	33 months
Unrecognized Compensation Cost	$ 0
Vesting Dates	11/1/2017
RSUs | 3/17/16 RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,016
Shares/Units | shares	130,006
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 34.78
Total Compensation Cost	$ 4.6	[1]
Weighted Average Period of Expense Recognition	33 months
Unrecognized Compensation Cost	$ 2
Vesting Dates	12/31/2018
RSUs | 1/1/2017 RSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,017
Shares/Units | shares	140,416
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 31.26
Total Compensation Cost	$ 4.3	[1]
Weighted Average Period of Expense Recognition	36 months
Unrecognized Compensation Cost	$ 3.3
Vesting Dates	12/31/2019
TSR PRSUs and LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/Units | shares	1,096,148
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 12.69
Total Compensation Cost	$ 13.9	[1]
Unrecognized Compensation Cost	$ 8
TSR PRSUs and LTIP Units | 2016 TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,014
Shares/Units | shares	135,634
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 8.67
Total Compensation Cost	$ 1.2	[1]
Weighted Average Period of Expense Recognition	48 months
Unrecognized Compensation Cost	$ 0.1
Performance Period	1/1/2014-12/31/2016
Vesting Dates	Quarterly in 2017
TSR PRSUs and LTIP Units | 3/31/15 2017 LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	137,249
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 14.66
Total Compensation Cost	$ 2	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 0.7
Performance Period	1/1/2015-12/31/2017
Vesting Dates	Quarterly in 2018
TSR PRSUs and LTIP Units | 4/1/2015 2017 LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	53,387
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 14.81
Total Compensation Cost	$ 0.8	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 0.2
Performance Period	1/1/2015-12/31/2017
Vesting Dates	Quarterly in 2018
TSR PRSUs and LTIP Units | 3/17/16 2018 LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,016
Shares/Units | shares	370,152
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 13.21
Total Compensation Cost	$ 4.9	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 2.9
Performance Period	1/1/2016-12/31/2018
Vesting Dates	Quarterly in 2019
TSR PRSUs and LTIP Units | 1/1/2017 2019 LTIP Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,017
Shares/Units | shares	399,726
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 12.61
Total Compensation Cost	$ 5	[1]
Weighted Average Period of Expense Recognition	48 months
Unrecognized Compensation Cost	$ 4.1
Performance Period	1/1/2017-12/31/2019
Vesting Dates	Quarterly in 2020
Relative TSR PRSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares/Units | shares	917,171
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 17.90
Total Compensation Cost	$ 16.4	[1]
Unrecognized Compensation Cost	$ 8.6
Relative TSR PRSUs | 2016 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,014
Shares/Units | shares	135,634
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 14.24
Total Compensation Cost	$ 1.9	[1]
Weighted Average Period of Expense Recognition	48 months
Unrecognized Compensation Cost	$ 0.1
Performance Period	1/1/2014-12/31/2016
Vesting Dates	Quarterly in 2017
Relative TSR PRSUs | 3/31/15 2017 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	137,249
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 22.50
Total Compensation Cost	$ 3.1	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 1
Performance Period	1/1/2015-12/31/2017
Vesting Dates	Quarterly in 2018
Relative TSR PRSUs | 4/1/2015 2017 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,015
Shares/Units | shares	53,387
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 22.92
Total Compensation Cost	$ 1.2	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 0.4
Performance Period	1/1/2015-12/31/2017
Vesting Dates	Quarterly in 2018
Relative TSR PRSUs | 3/17/16 2018 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,016
Shares/Units | shares	305,563
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 16.44
Total Compensation Cost	$ 5.1	[1]
Weighted Average Period of Expense Recognition	45 months
Unrecognized Compensation Cost	$ 2.9
Performance Period	1/1/2016-12/31/2018
Vesting Dates	Quarterly in 2019
Relative TSR PRSUs | 1/1/2017 2019 Relative TSR
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Year	2,017
Shares/Units | shares	285,338
Grant Date Average Fair Value Per Unit/ Share | $ / shares	$ 18.04
Total Compensation Cost	$ 5.1	[1]
Weighted Average Period of Expense Recognition	48 months
Unrecognized Compensation Cost	$ 4.2
Performance Period	1/1/2017-12/31/2019
Vesting Dates	Quarterly in 2020
[1]	Total compensation costs are net of shares cancelled.

STOCK-BASED COMPENSATION (Narra

STOCK-BASED COMPENSATION (Narrative) (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2017USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	2,441,989
Unrecognized compensation cost | $	$ 22.5
Percentage of operating partnership units distributions	10.00%
Restricted stock | Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	69,087
Vesting period, years	3 years
Unrecognized compensation cost | $	$ 1.7
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	428,670
Unrecognized compensation cost | $	$ 5.9
RSUs | January 1, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	140,416
LTIP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	1,096,148
Unrecognized compensation cost | $	$ 8
LTIP | January 1, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	399,726
Relative TSR PRSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	917,171
Unrecognized compensation cost | $	$ 8.6
Relative TSR PRSUs | January 1, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of restricted stock outstanding	285,338

BORROWING ACTIVITIES AND ARRA75

BORROWING ACTIVITIES AND ARRANGEMENTS (Details) - USD ($) $ in Thousands		Apr. 04, 2017	Sep. 30, 2017	Apr. 28, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Total secured borrowings - net	[1]		$ 53,419		$ 54,365
Revolving line of credit			365,000		190,000
Total term loans - net			903,221		1,094,343
Unsecured borrowings - net			3,322,888		3,028,146
Total secured and unsecured borrowings - net			$ 4,644,528		4,366,854
HUD mortgages assumed December 2011
Debt Instrument [Line Items]
Maturity	[2]		2,044
Rate	[2]		3.06%
Long-term Debt, Gross	[2]		$ 53,992		54,954
Deferred financing costs - net			$ (573)		(589)
Revolving line of credit
Debt Instrument [Line Items]
Maturity			2,021
Rate			2.49%
Revolving line of credit			$ 365,000		190,000
Term loan
Debt Instrument [Line Items]
Discounts and deferred financing costs - net	[3]		$ (5,759)		(5,657)
Tranche A-1 term loan
Debt Instrument [Line Items]
Long-term Debt, Gross					200,000
Tranche A-2 term loan
Debt Instrument [Line Items]
Long-term Debt, Gross					200,000
Tranche A-3 term loan
Debt Instrument [Line Items]
Long-term Debt, Gross					350,000
U.S. term loan
Debt Instrument [Line Items]
Maturity			2,022
Rate			2.69%
Total term loans - net			$ 425,000
Sterling term loan
Debt Instrument [Line Items]
Maturity			2,022
Rate			1.70%
Long-term Debt, Gross			$ 133,980
Omega OP Term loan
Debt Instrument [Line Items]
Maturity	[1]		2,022
Rate	[1]		2.69%
Long-term Debt, Gross	[1]		$ 100,000		100,000
Deferred financing costs - net			$ (600)
2015 term loan
Debt Instrument [Line Items]
Maturity			2,022
Rate			3.80%
Long-term Debt, Gross			$ 250,000		250,000
Unsecured debt excluding revolving credit facility and term loan
Debt Instrument [Line Items]
Deferred financing costs - net			(26,903)		(27,703)
Discount - net			$ (21,709)		(17,151)
2023 notes
Debt Instrument [Line Items]
Maturity			2,023
Rate			4.375%
Long-term Debt, Gross			$ 700,000		700,000
2024 notes
Debt Instrument [Line Items]
Maturity			2,024
Rate			5.875%	5.875%
Long-term Debt, Gross					400,000
2024 notes
Debt Instrument [Line Items]
Maturity			2,024
Rate			4.95%
Long-term Debt, Gross			$ 400,000		400,000
2025 notes
Debt Instrument [Line Items]
Maturity		2,025	2,025
Rate		4.50%	4.50%
Long-term Debt, Gross			$ 400,000		250,000
2026 notes
Debt Instrument [Line Items]
Maturity			2,026
Rate			5.25%
Long-term Debt, Gross			$ 600,000		600,000
2027 notes
Debt Instrument [Line Items]
Maturity			2,027
Rate			4.50%
Long-term Debt, Gross			$ 700,000		700,000
2028 notes
Debt Instrument [Line Items]
Maturity		2,028	2,028
Rate		4.75%	4.75%
Long-term Debt, Gross			$ 550,000
Subordinated debt
Debt Instrument [Line Items]
Maturity			2,021
Rate			9.00%
Long-term Debt, Gross			$ 20,000		20,000
Other
Debt Instrument [Line Items]
Maturity			2,018
Long-term Debt, Gross			$ 1,500		$ 3,000
[1]	These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.
[2]	Reflects the weighted average annual contractual interest rate on the mortgages at September 30, 2017 excluding a third-party administration fee of approximately 0.5% annually. Secured by real estate assets with a net carrying value of $62.9 million as of September 30, 2017.
[3]	This amount includes $0.6 million of net deferred financing costs related to the Omega OP term loan as of September 30, 2017.

BORROWING ACTIVITIES AND ARRA76

BORROWING ACTIVITIES AND ARRANGEMENTS (Parentheticals) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
HUD mortgages assumed December 2011
Debt Instrument [Line Items]
Percentage of third-party administration fee	0.50%
Real estate assets with a net carrying value	$ 62,900
Debt Issuance Costs, Net	573	$ 589
Omega OP Term loan
Debt Instrument [Line Items]
Debt Issuance Costs, Net	$ 600

BORROWING ACTIVITIES AND ARRA77

BORROWING ACTIVITIES AND ARRANGEMENTS (Narrative) (Detail) $ in Thousands, £ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
	May 25, 2017USD ($)	Jun. 30, 2017USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	May 25, 2017GBP (£)	Dec. 31, 2016USD ($)
Debt Instrument [Line Items]
Long-term line of credit			$ 365,000			$ 190,000
Repayment of Term loan/facility			1,312,000	$ 1,141,000
2017 Omega Credit Facilities
Debt Instrument [Line Items]
Long-term line of credit	$ 1,800,000
Maximum borrowing capacity	2,500,000
Revolving credit facility to be drawn in Alternative Currencies or U.S. Dollars in tranche one	900,000
Revolving credit facility to be drawn in Alternative Currencies or U.S. Dollars in tranche two	350,000
Revolving Credit Facility
Debt Instrument [Line Items]
Long-term line of credit			$ 365,000			$ 190,000
Maximum borrowing capacity	$ 1,250,000
Description of variable rate basis	LIBOR
Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Basis Spread on Variable Rate	1.00%
Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Basis Spread on Variable Rate	1.95%
U.S. Term Loan Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 425,000
Description of variable rate basis	LIBOR
U.S. Term Loan Facility | Minimum
Debt Instrument [Line Items]
Basis Spread on Variable Rate	0.90%
U.S. Term Loan Facility | Maximum
Debt Instrument [Line Items]
Basis Spread on Variable Rate	1.90%
Sterling Term Loan Facility
Debt Instrument [Line Items]
Maximum borrowing capacity | £					£ 100
Description of variable rate basis	LIBOR
Sterling Term Loan Facility | Minimum
Debt Instrument [Line Items]
Basis Spread on Variable Rate	0.90%
Sterling Term Loan Facility | Maximum
Debt Instrument [Line Items]
Basis Spread on Variable Rate	1.90%
Tranche A-1 term loan
Debt Instrument [Line Items]
Term loan/facility terminated	$ 200,000
Tranche A-2 term loan
Debt Instrument [Line Items]
Repayment of Term loan/facility	200,000
Term loan/facility terminated	200,000
Tranche A-3 term loan
Debt Instrument [Line Items]
Term loan/facility terminated	350,000
Senior unsecured 2014 revolving credit facility
Debt Instrument [Line Items]
Term loan/facility terminated	1,250,000
2014 Omega Credit Facilities
Debt Instrument [Line Items]
Write-off of deferred financing costs		$ 5,500
Amended 2015 Term Loan Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 250,000
Description of variable rate basis	LIBOR
Maturity date	Dec. 16, 2022
Maximum aggregate principal amount available under credit facility	$ 150,000
Amount of guaranty of unsecured indebtedness	$ 50,000
Amended 2015 Term Loan Facility | Minimum
Debt Instrument [Line Items]
Basis Spread on Variable Rate	1.40%
Amended 2015 Term Loan Facility | Maximum
Debt Instrument [Line Items]
Basis Spread on Variable Rate	2.35%
2017 Omega OP Term Loan Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 100,000
Description of variable rate basis	LIBOR
Maturity date	May 25, 2022
Amount of guaranty of unsecured indebtedness	$ 50,000
2017 Omega OP Term Loan Facility | Minimum
Debt Instrument [Line Items]
Basis Spread on Variable Rate	0.90%
2017 Omega OP Term Loan Facility | Maximum
Debt Instrument [Line Items]
Basis Spread on Variable Rate	1.90%

BORROWING ACTIVITIES AND ARRA78

BORROWING ACTIVITIES AND ARRANGEMENTS (Narrative) (Detail 1) - USD ($) $ in Millions	Apr. 05, 2017	Apr. 04, 2017	Apr. 28, 2017	Sep. 30, 2017
Debt Instrument [Line Items]
Net proceeds from the offering after deducting underwriting discounts and expenses		$ 690.7
4.75% notes due 2028
Debt Instrument [Line Items]
Maturity		2,028		2,028
Rate		4.75%		4.75%
Aggregate principal amount		$ 550
Maturity date		Jan. 15, 2028
Percentage of notes sold at an issue price		98.978%
4.50% notes due 2025
Debt Instrument [Line Items]
Maturity		2,025		2,025
Rate		4.50%		4.50%
Aggregate principal amount		$ 150
Maturity date		Jan. 15, 2025
Percentage of notes sold at an issue price		99.54%
5.875% notes due 2024
Debt Instrument [Line Items]
Maturity				2,024
Rate			5.875%	5.875%
Aggregate principal amount			$ 400
Redemption related costs and write offs			16.5
Call premium			11.8
Net write-offs associated with unamortized deferred financing costs			$ 4.7
Tranche A-2 term loan
Debt Instrument [Line Items]
Prepay senior unsecured incremental term loan facility	$ 200

FINANCIAL INSTRUMENTS (Detail)

FINANCIAL INSTRUMENTS (Detail) - USD ($) $ in Thousands		Sep. 30, 2017	Dec. 31, 2016
Assets:
Investments in direct financing leases - net		$ 364,997	$ 601,938
Mortgage notes receivable - net		666,606	639,343
Other investments - net		273,821	256,846
Liabilities:
Revolving line of credit		365,000	190,000
2015 term loan		903,221	1,094,343
HUD debt - net	[1]	53,419	54,365
Carrying Amount
Assets:
Investments in direct financing leases - net		364,997	601,938
Mortgage notes receivable - net		666,606	639,343
Other investments - net		273,821	256,846
Total		1,305,424	1,498,127
Liabilities:
Revolving line of credit		365,000	190,000
Tranche A-1 term loan			198,830
Tranche A-2 term loan			200,000
Tranche A-3 term loan			347,449
U.S. term loan		422,357
Sterling term loan		133,167
Omega OP term loan		99,390	100,000
2015 term loan		248,308	248,064
HUD debt - net	[1]	53,419	54,365
Subordinated debt - net		20,403	20,490
Other		1,500	3,000
Total		4,644,528	4,366,854
Carrying Amount | 4.375% notes due 2023
Liabilities:
Notes Payable		693,182	692,305
Carrying Amount | 5.875% notes due 2024
Liabilities:
Notes Payable			395,065
Carrying Amount | 4.95% notes due 2024
Liabilities:
Notes Payable		393,427	392,669
Carrying Amount | 4.50% notes due 2025
Liabilities:
Notes Payable		394,450	245,949
Carrying Amount | 5.25% notes due 2026
Liabilities:
Notes Payable		594,145	593,616
Carrying Amount | 4.50% notes due 2027
Liabilities:
Notes Payable		686,150	685,052
Carrying Amount | 4.75% notes due 2028
Liabilities:
Notes Payable		539,630
Fair Value
Assets:
Investments in direct financing leases - net		364,997	598,665
Mortgage notes receivable - net		681,274	644,961
Other investments - net		268,559	253,385
Total		1,314,830	1,497,011
Liabilities:
Revolving line of credit		365,000	190,000
Tranche A-1 term loan			200,000
Tranche A-2 term loan			200,000
Tranche A-3 term loan			350,000
U.S. term loan		425,000
Sterling term loan		133,980
Omega OP term loan		100,000	100,000
2015 Term loan		250,000	250,000
HUD debt - net	[1]	52,778	52,510
Subordinated debt - net		23,946	23,944
Other		1,500	3,000
Total		4,814,071	4,444,772
Fair Value | 4.375% notes due 2023
Liabilities:
Notes Payable		723,921	693,505
Fair Value | 5.875% notes due 2024
Liabilities:
Notes Payable			432,938
Fair Value | 4.95% notes due 2024
Liabilities:
Notes Payable		424,607	406,361
Fair Value | 4.50% notes due 2025
Liabilities:
Notes Payable		409,281	249,075
Fair Value | 5.25% notes due 2026
Liabilities:
Notes Payable		634,839	611,461
Fair Value | 4.50% notes due 2027
Liabilities:
Notes Payable		704,374	681,978
Fair Value | 4.75% notes due 2028
Liabilities:
Notes Payable		$ 564,845
[1]	These amounts represent borrowings that were incurred by Omega OP or wholly owned subsidiaries of Omega OP.

FINANCIAL INSTRUMENTS (Parenthe

FINANCIAL INSTRUMENTS (Parentheticals) (Detail)	Sep. 30, 2017	Apr. 28, 2017	Apr. 04, 2017
4.375% notes due 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.375%
5.875% notes due 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	5.875%	5.875%
4.95% notes due 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.95%
4.50% notes due 2025
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.50%		4.50%
5.25% notes due 2026
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	5.25%
4.50% notes due 2027
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.50%
4.75% notes due 2028
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Notes issued, interest rate	4.75%		4.75%

EARNINGS PER SHARE_UNIT - Compu

EARNINGS PER SHARE/UNIT - Computation of basic and diluted earnings per share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Numerator:
Net (loss) income	$ (137,515)	$ 82,134	$ 39,754	$ 253,484
Less: net loss (income) attributable to noncontrolling interests	5,837	(3,585)	(1,735)	(11,328)
Net (loss) income available to common stockholders	$ (131,678)	$ 78,549	$ 38,019	$ 242,156
Denominator:
Denominator for basic earnings per share	197,890	194,123	197,445	190,444
Effect of dilutive securities:
Common stock equivalents		1,093	271	1,174
Omega OP Unit equivalents	8,772	8,862	8,786	8,910
Denominator for diluted earnings per share	206,662	204,078	206,502	200,528
Earnings per share - basic:
Net (loss) income available to common stockholders (in dollars per share)	$ (0.67)	$ 0.40	$ 0.19	$ 1.27
Earnings per share - diluted:
Net (loss) income (in dollars per share)	$ (0.67)	$ 0.40	$ 0.19	$ 1.26
Omega OP
Numerator:
Net (loss) income	$ (137,515)	$ 82,134	$ 39,754	$ 253,484
Denominator:
Denominator for basic earnings per unit	206,662	202,985	206,231	199,354
Effect of dilutive securities:
Omega OP Unit equivalents		1,093	271	1,174
Denominator for diluted earnings per unit	206,662	204,078	206,502	200,528
Earnings per unit - basic:
Net (loss) income available to Omega OP Unit holders (in dollars per share)	$ (0.67)	$ 0.40	$ 0.19	$ 1.27
Earnings per unit - diluted:
Net (loss) income (in dollars per share)	$ (0.67)	$ 0.40	$ 0.19	$ 1.26

SUPPLEMENTAL DISCLOSURE TO CO82

SUPPLEMENTAL DISCLOSURE TO CONSOLIDATED STATEMENTS OF CASH FLOWS (Details) - Parent company - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Interest paid during the period, net of amounts capitalized	$ 147,266	$ 116,169
Taxes paid during the period	3,124	1,662
Non cash investing activities
Non cash acquisition of real estate (See Note 2)	(27,170)	0
Non cash acquisition of business	0	(60,079)
Non cash surrender of mortgage	0	25,000
Non cash investment in other investments	(6,353)	0
Non cash proceeds from other investments (see Note 5)	30,187	5,500
Non cash settlement of direct financing lease (See Note 3)	18,989	0
Total	15,653	(29,579)
Non cash financing activities
Purchase option buyout obligation	0	29,579
Change in fair value of cash flow hedges	(276)	12,094
Other unsecured long term borrowing	0	3,000
Remeasurement of debt denominated in a foreign currency	5,920	0
Total	$ 5,644	$ 44,673